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Supplement introduction
W
elcome to the third Supplement to the Health 
Technology Assessment journal series. The series 
is now over 10 years old and has published more 
than 400 titles, covering a wide range of health 
technologies in a diverse set of applications. In 
general, the series publishes each technology 
assessment as a separate issue within each annual 
volume. 
The Supplements depart from that format by 
containing a series of shorter articles. These are all 
products from a ‘call-off contract’, which the HTA 
programme holds with a range of academic centres 
around the UK, at the universities of Aberdeen, 
Birmingham, Exeter, Liverpool, Sheffield, 
Southampton and York. These centres are retained 
to provide a highly responsive resource, which 
meets the needs of national policy makers, notably 
the National Institute for Health and Clinical 
Excellence (NICE).
Until recently, these HTA Technology Assessment 
Review (TAR) centres provided academic input to 
policy making through independent analyses of 
the impact and value of health technologies. As 
many readers will be aware, the perception that 
the advice NICE provides to the NHS could be 
made more timely has led to the development of 
the ‘Single Technology Appraisal’ process. In this 
approach, manufacturers of technologies, which 
are, in general, pharmaceuticals close to the time 
of launch, submit a dossier of evidence aiming to 
demonstrate effectiveness and cost-effectiveness. 
The independent academic input to NICE’s 
process, which continues to be supported by the 
TAR centres around the UK under contract to the 
HTA programme, is to scrutinise, critique and 
explore this dossier of evidence.
The papers included in this Supplement report 
on this HTA programme funded work, and we 
hope that the summaries of the work carried out 
to inform the development of NICE guidance for 
these technologies will be of interest and value to 
readers. 
Further details of each of the NICE Appraisals are 
available on the NICE website (www. nice.org.uk) 
and we welcome comments on the summaries via 
the HTA website (www.hta.ac.uk/correspond).
Prof. Tom Walley 
Director, NIHR HTA programme 
Editor-In-Chief, Health Technology Assessment
Prof. Ken Stein 
Chair, Editorial Board, Health Technology AssessmentHealth Technology Assessment 2009; Vol. 13: Suppl. 3
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of lapatinib for 
the treatment of advanced or metastatic HER2-
overexpressing breast cancer based upon a review 
of the manufacturer’s submission to the National 
Institute for Health and Clinical Excellence (NICE) 
as part of the single technology appraisal (STA) 
process. The scope included women with advanced, 
metastatic or recurrent HER2-overexpressing 
breast cancer who have had previous therapy that 
includes trastuzumab. Outcomes were time to 
progression, progression-free survival, response 
rates, overall survival, health-related quality 
of life and adverse effects. The submission’s 
evidence came from one randomised controlled 
trial (RCT) of reasonable methodological 
quality, although it was not powered to detect a 
statistically significant difference in mean overall 
survival. Median time to progression was longer 
in the lapatinib plus capecitabine arm than in 
the capecitabine monotherapy arm {27.1 [95% 
confidence interval (CI) 17.4 to 49.4] versus 18.6 
[95% CI 9.1 to 36.9] weeks; hazard ratio 0.57 [95% 
CI 0.43 to 0.77; p = 0.00013]}. Median overall 
survival was very similar between the groups [67.7 
(95% CI 58.9 to 91.6) versus 66.6 (95% CI 49.1 
to 75.0) weeks; hazard ratio 0.78 (95% CI 0.55 
to 1.12; p = 0.177)]. Median progression-free 
survival was statistically significantly longer in 
the lapatinib plus capecitabine group than in the 
capecitabine monotherapy group [27.1 (95% CI 
24.1 to 36.9) versus 17.6 (95% CI 13.3 to 20.1) 
weeks; hazard ratio 0.55 (95% CI 0.41 to 0.74); 
p = 0.000033]. The manufacturer’s economic 
model to estimate progression-free and overall 
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survival for patients with HER2-positive advanced/
metastatic breast cancer who had relapsed 
following treatment with an anthracycline, a taxane 
and trastuzumab was appropriate for the disease 
area. The base-case incremental cost-effectiveness 
ratios (ICERs) for lapatinib plus capecitabine 
compared with capecitabine monotherapy or 
vinorelbine monotherapy were higher than would 
conventionally be considered cost-effective. 
When compared with trastuzumab-containing 
regimes, lapatinib plus capecitabine dominated. 
In sensitivity analyses the ICER for lapatinib 
plus capecitabine compared with capecitabine 
monotherapy or vinorelbine monotherapy was 
robust to variation in assumptions. In all sensitivity 
analyses the ICERs remained higher than would 
conventionally be considered cost-effective. 
ICERs for trastuzumab-containing regimes were 
particularly sensitive to assumptions over the 
frequency of treatment, which had a large effect on 
the cost-effectiveness of lapatinib plus capecitabine. 
In conclusion, there was a general lack of evidence 
on the effectiveness of comparators included in 
the model and on key parameters such as dose 
adjustments and the model outputs need to be 
interpreted in the light of this uncertainty. At the 
time of writing, NICE were still considering the 
available evidence for this appraisal.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
of the clinical effectiveness and cost-effectiveness 
of lapatinib for the treatment of metastatic breast 
cancer.
Description of the 
underlying health problem
Breast cancer is the most common cancer in the 
UK, accounting for one-third of all cancers in 
women.2 Increasing age is the strongest risk factor 
for breast cancer, and the disease is rare in women 
under the age of 40. 
In 2004 there were 36,939 new cases of breast 
cancer in women in England, which represents a 
crude rate of 144.6 per 100,000 women.3 In 2005 
there were 2364 new registrations in Wales, giving 
a rate of 155.4 per 100,000 women. These figures 
equate to age-standardised rates per 100,000 
population of 120.7 [95% confidence interval 
(CI) 119.5 to 121.9] for England and 120.8 (95% 
CI 115.9 to 125.7) for Wales.4 A recent review by 
the Office for National Statistics5 found a 20-year 
survival rate of 64% for women diagnosed with 
breast cancer between the ages of 50 and 69 years. 
Breast cancer is classified on a clinical basis 
according to the internationally recognised 
tumour, node, metastases (TNM) staging system.6 
The TNM system is based on three sets of codes 
relating to the primary tumour, involvement of 
lymph nodes and evidence of distant metastases. 
Four clinical stages are defined by particular 
combinations of these codes. Stage IV is metastatic 
disease, regardless of lymph node assessment or 
size of primary tumour. Approximately 25–30% of 
people with metastatic breast cancer have HER2-
positive disease, that is, their tumours overexpress 
the HER2 gene.7
Scope of the ERG report
The ERG critically evaluated the evidence 
submission from GlaxoSmithKline UK for the 
use of lapatinib for the treatment of advanced 
or metastatic ErbB2 (HER2: human epidermal 
growth factor receptor 2)-overexpressing breast 
cancer, in accordance with the predicted licensed 
indication. Lapatinib is a dual kinase inhibitor 
of epidermal growth factor receptor (ErbB1) and 
HER2 (ErbB2). It works intracellularly and, unlike 
monoclonal antibodies, it can block signalling 
through receptors that have lost or mutated their 
extracellular domains. Lapatinib is administered 
orally, in conjunction with capecitabine. 
At the time of writing, lapatinib had not yet 
received its marketing authorisation. The final 
scope issued by NICE stated that the population 
should be women with advanced, metastatic or Health Technology Assessment 2009; Vol. 13: Suppl. 3
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recurrent breast cancer that overexpresses the 
HER2 receptor who have had previous therapy that 
includes trastuzumab. The outcomes stated in the 
manufacturer’s definition of the decision problem 
were time to progression (primary end point), 
progression-free survival, response rates, overall 
survival, health-related quality of life and adverse 
effects. 
Methods
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process. 
The ERG checked the literature searches and 
applied the NICE critical appraisal checklist to 
the included studies and checked the quality of 
the manufacturer’s submission with the Centre 
for Reviews and Dissemination (CRD) quality 
assessment criteria for a systematic review. 
In addition, the ERG checked and provided 
commentary on the manufacturer’s model using 
standard checklists. A one-way sensitivity analysis, 
scenario analysis and a probabilistic sensitivity 
analysis (PSA) were undertaken by the ERG. 
The cost-effectiveness acceptability curves for 
capecitabine monotherapy and lapatinib plus 
capecitabine from the ERG’s PSA are shown in 
Figure 1. 
Results 
Summary of submitted 
clinical evidence
The main evidence in the submission came 
from one multicentre, multinational, open-label 
randomised controlled trial (RCT), EGF100151. 
Interim analyses from the trial were published in 
2006, but the evidence in the report was from a 
later time point. These later data were expected 
to be published in June 2007,8 but had not been 
published when the ERG report and this summary 
were written.
Median time to progression was longer in the 
lapatinib plus capecitabine arm than in the 
capecitabine monotherapy arm [27.1 weeks (95% 
CI 17.4 to 49.4) versus 18.6 weeks (95% CI 9.1 to 
36.9)], although the CIs overlapped. The hazard 
ratio reported in the manufacturer’s submission 
was 0.57 (95% CI 0.43 to 0.77; p = 0.00013). 
Median overall survival was very similar between 
the two groups [67.7 weeks (95% CI 58.9 to 
91.6) versus 66.6 weeks (95% CI 49.1 to 75.0) for 
lapatinib plus capecitabine versus capecitabine 
monotherapy respectively)]. The hazard ratio was 
0.78 (95% CI 0.55 to 1.12; p = 0.177). 
Median progression-free survival was statistically 
significantly longer in the lapatinib plus 
capecitabine group than in the capecitabine 
monotherapy group [27.1 weeks (95% CI 24.1 
to 36.9) versus 17.6 weeks (95% CI 13.3 to 
20.1); hazard ratio 0.55 (95% CI 0.41 to 0.74); 
p = 0.000033]. 
Summary of submitted cost-
effectiveness evidence
The cost-effectiveness analysis used survival 
modelling methodology to estimate progression-
free and overall survival for patients with HER2-
positive advanced/metastatic breast cancer who had 
relapsed following treatment with an anthracycline, 
a taxane and trastuzumab. The incremental costs 
and consequences of treatment with lapatinib plus 
capecitabine were estimated relative to each of 
five different comparator regimes. Comparators 
were capecitabine monotherapy, vinorelbine 
monotherapy, trastuzumab monotherapy, 
trastuzumab plus capecitabine and trastuzumab 
plus vinorelbine.
The model was generally internally consistent and 
appropriate to metastatic breast cancer in terms of 
structural assumptions, although it used a different 
approach from previous economic evaluations of 
treatments for metastatic breast cancer.9–13 The 
cost-effectiveness analysis generally conformed to 
the NICE reference case and the scope/decision 
problem. 
Treatment effects for lapatinib plus capecitabine 
and capecitabine monotherapy were derived from 
direct clinical trial evidence. In the absence of data 
on the effectiveness of vinorelbine monotherapy, it 
was assumed to be identical to that of capecitabine 
monotherapy. The effectiveness of trastuzumab-
containing regimes was based on pooling of data 
on time to disease progression, which was used in 
an unadjusted indirect comparison.
Utilities for preprogression survival were based 
on responses to the EuroQol 5 dimensions (EQ-
5D) questionnaire in the EGF100151 trial. There 
were substantial missing data for the quality of 
life assessment in the trial. The utility reduction Lapatinib for the treatment of HER2-overexpressing breast cancer
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following disease progression was based on 
a published study,14 which reported general 
population valuations of disease progression and 
the impact of treatment-related adverse events.
The base-case incremental cost-effectiveness 
ratios (ICERs) for lapatinib plus capecitabine 
compared with capecitabine monotherapy or 
vinorelbine monotherapy were higher than would 
conventionally be considered cost-effective. When 
compared with trastuzumab-containing regimes, 
lapatinib plus capecitabine dominated (i.e. gave 
improved outcome at lower cost).
Sensitivity analyses reported in the manufacturer’s 
submission and undertaken by the ERG showed 
that the ICER for lapatinib plus capecitabine 
compared with capecitabine monotherapy or 
vinorelbine monotherapy was robust to variation in 
assumptions. In all sensitivity analyses the ICERs 
remained higher than would conventionally be 
considered cost-effective. ICERs for trastuzumab-
containing regimes were highly sensitive to 
assumptions over the frequency of treatment 
(weekly or three-weekly), the distribution of 
weight and body surface area of patients receiving 
treatment, and wastage for infusional regimes.
Commentary on 
the robustness of 
submitted evidence
Strengths
The manufacturer’s submission was well written 
and presented a clear description of the evidence 
base. The manufacturer conducted a systematic 
review for this appraisal and searched all relevant 
databases using appropriate search strategies. 
The identified RCT EGF100151 appeared to be 
of reasonable methodological quality, although 
enrolment was terminated before the required 
sample size had been met.
The economic model presented with the 
manufacturer’s submission used an appropriate 
approach for the disease area and given the 
available data.
Weaknesses
There was some deviation from the scope issued 
by NICE in terms of the timing of previous lines of 
therapy, and of comparator treatments. 
FIGURE 1  Cost-effectiveness acceptability curves for capecitabine monotherapy and lapatinib plus capecitabine from the ERG’s 
probabilistic sensitivity analysis. QALY, quality-adjusted life-year.
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Only one relevant RCT was identified by the 
manufacturer’s systematic review and the 
evidence base for lapatinib plus capecitabine in 
the manufacturer’s submission was largely based 
on this one trial. Early termination of enrolment 
meant that there was insufficient power to detect a 
statistically significant difference in mean overall 
survival. 
The trastuzumab studies pooled for an indirect 
comparison contained a variety of treatment 
regimens. None of the studies contained a 
capecitabine monotherapy arm and so it was 
not possible for the manufacturer to perform an 
adjusted indirect comparison.15 The manufacturer 
therefore used a methodologically weaker 
unadjusted indirect comparison. The resulting 
pooled mean of median time to progression values 
for trastuzumab may not be a reliable estimate and 
should therefore be treated with caution. 
There was no evidence in the manufacturer’s 
submission of a systematic search for model 
parameters, in particular cost inputs and utilities.
Conclusions 
Areas of uncertainty
Trastuzumab monotherapy was included as a 
comparator. Consultation with clinical advisors 
suggested that trastuzumab is used beyond 
progression in combination with chemotherapy 
agents in some primary care trusts, but not others. 
Clinical advisors indicated that trastuzumab 
monotherapy is unlikely to be continued beyond 
disease progression. 
The manufacturer’s submission included a post hoc 
subgroup analysis of patients with brain metastases. 
It is likely that this is underpowered and so it 
should be treated with caution. 
There was a lack of robust and reliable evidence 
on the effectiveness of the majority of comparators 
included in the economic model (vinorelbine 
monotherapy and all of the trastuzumab-
containing regimes).
There was uncertainty over the pattern of 
treatment with trastuzumab if it is continued 
beyond disease progression, in particular whether 
treatment is weekly or three-weekly. This had a 
large effect on the cost-effectiveness of lapatinib 
plus capecitabine.
Key issues 
The included trial was not powered to detect 
a statistically significant difference in overall 
survival between lapatinib plus capecitabine and 
capecitabine monotherapy.
There was a general lack of evidence on the 
effectiveness of comparators included in the 
economic model. A lack of evidence on other key 
parameters (such as dose adjustments) meant that 
there was a great deal of uncertainty and model 
outputs need to be interpreted in the light of that 
uncertainty.
Summary of NICE guidance 
issued as a result of the STA 
At the time of writing, NICE were still considering 
the available evidence for this appraisal. 
Key references
1.  National Institute for Health and Clinical 
Excellence. Guide to the single technology (STA) process. 
19 September 2006. URL: www.nice.org.uk/page.
aspx?o=STAprocessguide.
2.  Office for National Statistics. Breast cancer: incidence 
rises while deaths continue to fall. 2005. URL: www.
statistics.gov.uk/cci/nugget_print.asp?ID=575. Cited 
1 December 2005.
3.  Office for National Statistics. Cancer statistics 
registrations: registrations of cancer diagnosed in 2004, 
England. Series MB1 No. 35. 2007. URL: www.
statistics.gov.uk/statbase/Product.asp?vlnk=8843. 
Cited 29 August 2007.
4.  Welsh Cancer Intelligence and Surveillance Unit. 
Cancer incidence in Wales. 2007. URL: www.wales.nhs.
uk/sites3/page.cfm?orgid=242&pid=21936.
5.  Rachet B, Coleman M, Cooper N, Quinn M, Wood 
H. Breast cancer survival, England and Wales, 1991–
2003. Predicted trends in long-term survival from breast 
cancer in women: age; and Government office region in 
England and Wales. 2006. URL: www.statistics.gov.uk/
statbase/ssdataset.asp?vlnk=9132&More=Y. Cited 1 
December 2005.
6.  Harris JR, Lippman ME, Veronesi U, Willett W. 
Breast cancer (2). N Engl J Med 1992;327:390–8.
7.  Penault-Llorca F, Vincent-Salomon A, Mathieu M, 
Trillet-Lenoir V, Khayat D, Marty M, et al. Incidence 
and implications of HER2 and hormonal receptor Lapatinib for the treatment of HER2-overexpressing breast cancer
6
overexpression in newly diagnosed metastatic breast 
cancer (MBC). J Clin Oncol 2005;23(16S):764.
8.  Geyer CE, Forster J, Lindquist D, Chan S, Romieu 
CG, Pienkowski T, et al. Lapatinib plus capecitabine 
for HER2-positive advanced breast cancer [see 
comment]. N Engl J Med 2006;355:2733–43.
9.  Brown RE, Hutton J. Cost–utility model comparing 
docetaxel and paclitaxel in advanced breast cancer 
patients. Anticancer Drugs 1998;9:899–907.
10.  Brown RE, Hutton J, Burrell A. Cost effectiveness of 
treatment options in advanced breast cancer in the 
UK. Pharmacoeconomics 2001;19:1091–1102.
11.  Cooper NJ, Abrams KR, Sutton AJ, Turner D, 
Lambert PC. A Bayesian approach to Markov 
modelling in cost-effectiveness analyses: application 
to taxane use in advanced breast cancer. J R Stat Soc 
Sers A Stat Soc 2003;166:389–405.
12.  Hutton J, Brown R, Borowitz M, Abrams K, 
Rothman M, Shakespeare A. A new decision model 
for cost–utility comparisons of chemotherapy 
in recurrent metastatic breast cancer. 
Pharmacoeconomics 1996;9(Suppl. 2):8–22.
13.  Launois R, Reboul-Marty J, Henry B, Bonneterre J. 
A cost–utility analysis of second-line chemotherapy 
in metastatic breast cancer. Docetaxel versus 
paclitaxel versus vinorelbine. Pharmacoeconomics 
1996;10:504–21.
14.  Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins 
J. Health state utilities for metastatic breast cancer. 
Br J Cancer 2006;95:683–90.
15.  Glenny A, Altman D, Song F, Sakarovitch C, 
Deeks J, D’Amico R, et al. Indirect comparisons 
of competing interventions. Health Technol Assess 
2005;9(26).Health Technology Assessment 2009; Vol. 13: Suppl. 3
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
7
Infliximab for the treatment of ulcerative colitis
C Hyde,* S Bryan, A Juarez-Garcia, L Andronis and 
A Fry-Smith 
West Midlands Health Technology Assessment Collaboration, Department of Public Health and 
Epidemiology, University of Birmingham, UK
*Corresponding author
Declared competing interests of authors: none
Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of infliximab 
for moderately to severely active ulcerative colitis 
(UC) based upon a review of the manufacturer’s 
submission to the National Institute for Health 
and Clinical Excellent (NICE) as part of the 
single technology appraisal (STA) process. The 
submission indicated that the efficacy of infliximab 
(5 mg/kg) had been demonstrated in terms of 
higher response rates and a sustained response 
in health-related quality of life. For the cost-
effectiveness analysis, the manufacturer built a 
Markov model to compare infliximab with standard 
care. It estimated the incremental cost per quality-
adjusted life-year (QALY) gained was between 
£25,044 and £33,866 depending on the strategy 
used. The ERG report generally agreed with the 
evidence on effectiveness of infliximab for subacute 
exacerbations of UC. However, there were several 
areas of uncertainty, of which the interpretation 
of the importance of the quality of life changes 
in the subacute situation and the assessment of 
the adequacy of the evidence of effectiveness of 
infliximab in the acute hospital-based situation 
were considered pre-eminent by the ERG. This 
challenged the estimates of cost-effectiveness 
offered and suggested that there should be a 
separate assessment of infliximab for acute 
exacerbations of moderately to severely active UC. 
The summary of the NICE guidance issued in April 
2008 as a result of the STA states that: infliximab 
is not recommended for the treatment of subacute 
manifestations of moderately to severely active UC.
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Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
of infliximab for ulcerative colitis (UC).2 This STA 
was subsequently split into two parts, infliximab for 
subacute manifestations of UC and infliximab for 
acute exacerbations of UC. The latter is the subject 
of a separate STA and report (08/37/01).
Description of the 
underlying health problem
Ulcerative colitis is a chronic condition in which 
there is inflammation of the mucosa of the large 
intestine. The incidence of UC is approximately 
10–20 per 100,000 per year with a reported 
prevalence of 100–200 per 100,000 in the UK. 
The symptoms of UC vary according to the extent 
and severity of the inflammation. The classic 
symptom of UC is bloody diarrhoea. Associated 
symptoms of colicky abdominal pain, urgency 
or tenesmus may be present. Mildly active UC is 
defined as less than four bowel movements daily. 
Moderately active UC is defined as more than 
four bowel movements daily, but when the patient 
is not systemically ill. Severe UC is defined as an 
attack in which the patient has more than six bowel 
movements daily and is systemically ill as shown by 
tachycardia, fever and anaemia. Fulminant disease 
correlates with more than 10 bowel movements 
daily, continuous bleeding, toxicity, abdominal 
tenderness and distension, blood transfusion 
requirement and colonic dilatation (expansion). 
In UC the severity of the symptoms fluctuates 
unpredictably over time with intervals of remission 
or reduced symptoms. Approximately 50% of 
patients with UC have a relapse in any year. A 
significant minority have frequently relapsing 
or chronic continuous disease. In total, 25% 
of patients with severe UC are admitted to an 
inpatient setting with flares of UC that are not 
responding to steroids. An estimated 20–30% of 
patients with pancolitis (disease affecting the entire 
colon) will require colectomy. 
The British Society of Gastroenterology published 
guidelines for the treatment of UC in 2004. 
The main recommendations for the medical 
management of active left-sided or extensive 
UC are treatment with oral aminosalicylates 
or corticosteroids. In active distal UC (i.e. 
colitis confined to the rectum, or rectum and 
sigmoid colon) treatment options include topical 
mesalazine, or topical corticosteroids combined 
with oral mesalazine, or systemic corticosteroids. 
When in remission patients with UC should 
normally receive maintenance therapy with 
aminosalicylates, azathioprine or mercaptopurine 
to reduce the risk of relapse. Patients frequently 
receive combination therapies. Severe UC should 
be managed jointly by a gastroenterologist in 
conjunction with a colorectal surgeon. 
Infliximab (Remicade®, Schering-Plough) is a 
chimeric monoclonal antibody that binds with 
high affinity to tumour necrosis factor (TNF)-a, 
thereby neutralising its activity. It is administered 
by intravenous infusion and is licensed for use 
in rheumatoid arthritis, active Crohn’s disease, 
psoriasis, psoriatic arthritis and ankylosing 
spondylitis as well as in UC. 
Infliximab is licensed for moderately to severely 
active UC in patients who have had an inadequate 
response to conventional therapy including 
corticosteroids and 6-mercaptopurine or 
azathioprine, or who are intolerant to or who have 
medical contraindications to such therapies. 
Scope of the ERG report
The purpose of the ERG report is to comment 
on the validity of the manufacturer’s submission 
on the technology of interest. The scope for this 
submission and hence the scope for the ERG 
report was to appraise the clinical effectiveness and 
cost-effectiveness of infliximab for moderately to 
severely active UC.Health Technology Assessment 2009; Vol. 13: Suppl. 3
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The population considered was adults with 
moderately to severely active UC who have had 
an inadequate response to conventional therapy 
including corticosteroids and 6-mercaptopurine or 
azathioprine, or who are intolerant to or who have 
medical contraindications to such therapies. The 
intervention was infliximab.
The standard comparators to be considered 
included standard care [which may include 
conventional therapy with a combination of 
5-aminosalicylic acid (5-ASA) compounds, 
corticosteroids and immunomodulators 
(azathioprine or 6-mercaptopurine)], ciclosporin 
and surgery.
The outcome measures to be considered included 
health-related quality of life, survival, measures of 
disease activity, rates of and duration of response, 
relapse and remission, rates of hospitalisation, 
reduction in use of corticosteroids, rates of surgical 
intervention and adverse effects of treatment.
For the economic analysis the reference case 
stipulates that the cost-effectiveness of treatments 
should be expressed in terms of incremental cost 
per quality-adjusted life-year (QALY). The time 
horizon should be long enough to allow reasonable 
estimation of expected costs (including adverse 
events if applicable) and benefits for each of the 
two clinical situations. Costs were considered from 
an NHS and personal social services perspective.
When evidence permitted, the appraisal of 
infliximab for moderate to severely active UC 
was to identify patient subgroups for whom the 
technology was most appropriate and to consider 
the length of treatment required when patients 
have responded to infliximab. Guidance was only 
to be issued in accordance with the summary of 
product characteristics.
Methods 
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process. 
Specific steps undertaken by the ERG included:
•  discussion of the nature of the problem with a 
clinical expert 
•  reanalysis of the nature of the underlying 
clinical question
•  rerunning searches indicated to have been 
carried out to inform the manufacturer’s 
submission 
•  extending searches, particularly for ongoing 
trials
•  a formal critical appraisal of the systematic 
review underpinning the manufacturer’s 
submission, and a related Cochrane review
•  reappraisal and checking of data abstraction on 
two key included studies
•  detailed checking of company reports 
(commercial-in-confidence data) of the pivotal 
trials
•  rerunning of meta-analyses, correcting errors 
in the submission
•  checking the consistency of the effectiveness 
estimates emerging from the systematic review 
with the parameters used in the economic 
model 
•  rerunning of the economic model supplied by 
the company
•  correction of an error in the reporting of the 
results of the economic model
•  additional sensitivity analyses within the limits 
of the facilities of the submitted model.
The work was carried out between 20 May 2007 
and 22 July 2007. Members of the ERG team 
attended and advised the meetings of the NICE 
appraisal committee where this guidance was 
discussed on 22 August 2007 and 20 November 
2007.
Results 
Summary of submitted 
clinical evidence
The submission attempted to systematically review 
the randomised controlled trial (RCT) evidence 
comparing infliximab with placebo. It used an 
existing Cochrane review as its starting point. The 
submission identified no new RCTs and included 
five RCTs, reported in four articles, which are well 
recognised. Three RCTs consider the subacute, 
outpatient application of infliximab and two 
consider the acute, hospital-based application, 
which is argued to be ‘off-label’ use.
The submission highlighted that the efficacy 
of infliximab at a dose of 5 mg/kg has been 
demonstrated, particularly by two large RCTs [ACT 
(Active Ulcerative Colitis Trial) I and II] in terms 
of higher response rates and a sustained response 
in health-related quality of life. Infliximab was well 
tolerated.Infliximab for the treatment of ulcerative colitis
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Summary of submitted cost-
effectiveness evidence
No published economic evaluations of infliximab 
in UC were identified and so the cost-effectiveness 
work focused almost entirely on the de novo 
model and economic evaluation undertaken by 
the manufacturer. A Markov model was built to 
compare two treatment strategies, infliximab 
versus standard care, in terms of costs and QALYs. 
The patient group modelled had moderately to 
severely active UC and included patients ‘who 
have had an inadequate response to conventional 
therapy including corticosteroids and 6-MP 
or AZA (6-mercaptopurine or azathioprine 
respectively), or who are intolerant to or have 
medical contraindications for such therapies’. The 
main submission only considered patients in this 
category (although the manufacturer’s clarification 
response included results for patients who were 
more severe, for whom surgery is the comparator 
considered). The modelling was undertaken, in 
part, using data from the ACT trials. 
The model followed a cohort of patients with 
moderate or severe UC from entry through to 10 
years, with patients being tracked as they moved 
between the nine states in the model. The cycle 
length was 8 weeks. The disease states in the model 
were defined as remission (Mayo score 0–2), mild 
(Mayo score 3–5) and moderate/severe (Mayo score 
6–12).
Two separate treatment strategies were evaluated, 
which differ in the assumption made about 
continuation of infliximab therapy. Strategy 
A modelled the continuation of infliximab 
in treatment responders who achieved and 
maintained remission or mild health states. In 
contrast, strategy B considered a narrower therapy 
continuation group defined as responders who 
achieve and maintain remission. The results of the 
economic analyses indicated that the incremental 
cost per QALY gained was £33,866 for strategy A 
and £25,044 for strategy B.
Commentary on 
the robustness of 
submitted evidence 
Strengths
The submission comprehensively ascertained all 
of the available RCTs comparing infliximab with 
placebo. This is in agreement with other reviews in 
the field. Helpful additional information on the key 
included RCTs was made available when requested.
The submission reported a de novo model-based 
economic evaluation that considered the cost-
effectiveness of infliximab in UC. The use of a 
Markov model is appropriate as the disease is 
characterised by progression over time and so a 
modelling approach that can deal with transition 
between states and the timing of events is required. 
The main transition probability inputs were 
derived from two relevant trials, the ACT trials, 
and many of the other inputs and parameters were 
based on appropriate data. Probabilistic sensitivity 
analysis (PSA) and one-way sensitivity analyses were 
performed.
Weaknesses
The review was generally poorly reported. The 
conduct of the review was at best adequate and 
there were some important deficiencies. For 
instance, several data abstraction errors were 
identified. Also the summary of the results of 
the included studies lacked clarity and the meta-
analyses attempted were incorrect. In the analysis 
the submission failed to clearly separate the results 
relating to subacute applications of infliximab from 
the acute applications in hospital. 
Despite the errors in the review of clinical evidence 
offered in the submission the ERG’s own summary 
suggests that portrayal of the effectiveness 
evidence in the manufacturer’s submission remains 
reasonably faithful. Infliximab is effective in 
increasing clinical response, remission and mucosal 
healing and in improving health-related quality 
of life in moderate to severe UC in the outpatient 
setting.
In terms of the submitted evidence on cost-
effectiveness there are serious concerns in relation 
to the appropriateness of the policy question 
being addressed and a judgement is required as 
to whether this question is the question of most 
interest to NICE. The manufacturer’s analysis 
considered the use of infliximab in patients with 
moderate to severe UC compared with standard 
care including 5-ASA compounds, corticosteroids 
and immunomodulators (azathioprine or 
6-mercaptopurine). However, the scope indicated 
that the question of interest for NICE was the 
use of infliximab in patients who have had an 
inadequate response to conventional therapy for 
whom the comparator technologies include surgery 
or ciclosporin. 
The manufacturer chose not to make use of the 
health utility data available from the ACT trials, Health Technology Assessment 2009; Vol. 13: Suppl. 3
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but rather commission a new cross-sectional study 
to gather new health utility data. Given that much 
of the input data for the model were taken from the 
ACT trials, this decision is surprising and requires 
justification. 
The model had a time horizon of 10 years for 
the base case, but the longest follow-up in the 
ACT trials was 54 weeks. Thus, the transition 
probabilities were derived from trial data up to 
54 weeks and were assumed to remain constant 
through to 10 years. 
The PSA was undertaken in a very partial 
manner, with distributions placed around selected 
parameters only. Errors in the interpretation of 
the PSA and calculation of the cost-effectiveness 
acceptability curve were identified.
Conclusions 
The key areas of uncertainty identified were: 
•  There is evidence on the effectiveness of 
infliximab in the acute hospital-based setting 
in terms of response and avoidance of surgery; 
however, the results are primarily based on 
one small study, even though the effect on 
colectomy rates is highly statistically significant.
•  The evidence on colectomy and ostomy rates 
in the subacute setting is unclear, and indeed 
there are some inconsistencies between 
different reports of hospitalisation rates from 
ACT I and II.
•  In ACT I and II, although the statistical 
significance of the differences in change in 
quality of life with infliximab compared with 
placebo are clear, the importance of these 
changes to the patient is less easy to define, an 
issue with a key bearing on the interpretation 
of the cost-effectiveness component of the 
submission.
•  In common with all newly introduced drugs 
the long-term safety of infliximab needs to be 
established, particularly with respect to the risk 
of malignancy. 
•  The definition of the policy question and, 
depending on the answer to this question, the 
appropriate trials from which to be drawing 
data.
•  A key driver of the model results is the 
utility data and so a judgement on the most 
appropriate source of utility data is required.
•  The robustness of the assumption concerning 
long-term follow-up to 10 years, given that this 
is based on trial data to 54 weeks.
Of these, the interpretation of the importance of 
the quality of life changes in the subacute situation 
and the assessment of the adequacy of the evidence 
of effectiveness of infliximab in the acute hospital-
based situation were considered pre-eminent by the 
ERG.
Summary of NICE guidance 
issued as a result of the STA 
At the time of writing, the guidance document 
issued by NICE in April 2008 states that: 
Infliximab is not recommended for the treatment 
of subacute manifestations of moderately to 
severely active ulcerative colitis. 
For the purposes of this guidance, a subacute 
manifestation of moderately to severely active 
ulcerative colitis is defined as disease that would 
normally be managed in an outpatient setting 
and that does not require hospitalisation or the 
consideration of urgent surgical intervention.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical and 
cost-effectiveness of rimonabant for the treatment 
of obese or overweight patients based upon a 
review of the manufacturer’s submission to the 
National Centre for Health and Clinical Excellence 
(NICE) as part of the single technology appraisal 
(STA) process. The submission’s main evidence 
came from four randomised controlled trials. 
Rimonabant resulted in a significantly greater 
benefit than placebo for all primary weight loss 
outcomes. At 1 year, rimonabant had a statistically 
significant beneficial effect on systolic blood 
pressure, high-density lipoprotein cholesterol, 
triglycerides and fasting plasma glucose in diabetics 
and non-diabetics, and glycosylated haemoglobin 
in diabetics. Improvements were maintained over 2 
years with rimonabant; withdrawal of rimonabant 
at 1 year resulted in a reduction in weight loss until 
there was no difference from placebo at 2 years. 
Psychiatric adverse events were experienced by 
26% and 14% of rimonabant and placebo patients 
respectively; figures for symptoms of depression 
were 9% and 5% respectively. Pairwise comparisons 
of orlistat, sibutramine and rimonabant showed 
beneficial effects of rimonabant over orlistat 
and sibutramine for weight loss outcomes; 
however, response hurdles imposed on orlistat or 
sibutramine in clinical practice may not have been 
applied in the orlistat and sibutramine trials. The 
manufacturer’s Markov cohort model evaluated 
rimonabant versus orlistat, sibutramine and diet 
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and exercise alone for three base-case populations. 
The incremental cost-effectiveness ratio (ICER) 
of rimonabant varied from £10,534–£13,236 
per quality-adjusted life-year (QALY) versus 
diet and exercise, to £8977–£12,138 per QALY 
versus orlistat, to £1463–£3908 per QALY versus 
sibutramine. In subgroup analysis there was a 
wider variation in the ICER estimates although 
none exceeded £20,000 per QALY. The ICER of 
rimonabant remained under £20,000 per QALY in 
reanalyses by the manufacturer and the ERG, with 
the results sensitive to the source of health-related 
quality of life (HRQoL) benefits in the model. Four 
treatment strategies were modelled in comparisons 
of rimonabant versus diet and exercise alone and 
orlistat and sibutramine in which rimonabant was 
continued only in patients achieving 5% weight loss 
at 3, 6, 9 or 12 months. In pairwise comparisons 
rimonabant remained below a threshold of £30,000 
per QALY in 70% of the comparisons reported. 
The results were most sensitive to the decrement 
applied to depression and the costs of screening 
for depression. In conclusion, areas of uncertainty 
remain in relation to the clinical effectiveness and 
cost-effectiveness of rimonabant, for example lack 
of evidence on long-term outcomes and the effect 
of rimonabant on cardiovascular events, developing 
diabetes and mortality, and lack of data on the 
HRQoL benefits associated with rimonabant. The 
lack of response hurdles applied to sibutramine 
and orlistat means that the comparator strategies 
were not considered by the ERG to reflect their 
respective product licenses or current NHS use. 
The NICE guidance issued as a result of the 
STA states that rimonabant is recommended as 
an adjunct to diet and exercise for adults who 
are obese or overweight and who have had an 
inadequate response to, are intolerant of or are 
contraindicated to orlistat and sibutramine.
Introduction 
The National Institute for Health Research 
Health Technology Assessment (NIHR HTA) 
programme supports the National Institute for 
Health and Clinical Excellence (NICE) by funding 
independent academic input to NICE technology 
appraisal activities. NICE is an independent 
organisation within the NHS that is responsible 
for providing national guidance on the treatment 
and care of people using the NHS in England and 
Wales. One of the responsibilities of NICE is to 
provide guidance to the NHS on the use of selected 
new and established health technologies, based on 
an appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a 
single product, device or other technology, with a 
single indication, for which most of the relevant 
evidence lies with one manufacturer or sponsor 
(Sanofi-Aventis).1 Typically, it is used for new 
pharmaceutical products close to launch. The 
principal evidence for an STA is derived from 
a submission by the manufacturer/sponsor of 
the technology to NICE. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
of rimonabant for the treatment of overweight and 
obese patients,2 which was submitted on 5 October 
2007 to NICE, with a subsequent submission of a 
commentary on 24 January 2008.
In October 2008, the European Medicines Agency 
(EMEA), based on new evidence that became 
available from postmarketing surveillance studies 
following the NICE appraisal of rimonabant, 
concluded that the balance of risks and benefits no 
longer supported the use of rimonabant and the 
drug was withdrawn from use. It should therefore 
be noted that this report is based only on evidence 
available to NICE at the time of its appraisal of 
rimonabant and does not include any further 
evidence that informed the EMEA’s decision on 
withdrawal.
Description of the 
underlying health problem
Obesity is a chronic condition which is associated 
with a number of conditions such as type 2 diabetes 
that have a significant impact on morbidity and 
quality of life and reduce life expectancy. There 
are currently several options for the treatment 
of overweight and obese patients, including 
lifestyle changes, drug treatments and bariatric 
surgery. According to NICE guidelines, the initial 
treatments of choice for overweight and obese 
patients are multicomponent interventions that 
include behavioural change strategies to promote 
physical activity and improve eating habits.
Three drugs are currently used in practice 
to treat obesity: orlistat (Xenical®, Roche), 
sibutramine (Reductil®, Abbott) and rimonabant 
(Accomplia®). Orlistat is a specific and long-acting 
inhibitor of the enzyme lipase, which results in 
the inability to hydrolyse dietary fat in the form 
of triglycerides into absorbable free fatty acids Health Technology Assessment 2009; Vol. 13: Suppl. 3
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and monoglycerides, therefore preventing fat 
absorption. The net price per 84-cap pack is 
£33.58, with an approximate annual cost of £438. 
Sibutramine produces secondary and primary 
amine metabolites that inhibit noradrenaline, 
serotonin and dopamine reuptake, which in turn 
suppresses appetite by producing a feeling of 
satiety. The net price per 28-cap pack of 10 mg is 
£36.90. The net price per 28-cap pack of 15 mg 
is £43.65. The approximate annual cost is £481 
for 10 mg and £569 for 15 mg. Rimonabant is a 
selective CB1 cannabinoid receptor antagonist and 
acts by decreasing appetite. The net price per 28-
tab pack is £44.00, with an approximate annual 
cost of £574.
The manufacturer’s submission to NICE stated 
that, since the introduction of rimonabant until the 
end of June 2007, approximately 32,500 patients 
have been prescribed rimonabant in England 
and Wales, accounting for 16.4% of prescription 
initiations for obesity treatments during that 
period. Patients with comorbidities accounted for a 
large majority of rimonabant prescriptions.
Concerns have been raised relating to the licensing 
of rimonabant, both in the UK and in the USA. In 
January 2007, the Scottish Medicines Consortium 
decided that the economic case for prescribing 
rimonabant had not been demonstrated and 
therefore did not recommend its use within NHS 
Scotland as an adjunct to diet and exercise for the 
treatment of obese or overweight patients. The US 
Food and Drugs Administration (FDA) also did not 
recommend a license for rimonabant in the USA 
because of the risk of psychiatric adverse events, 
particularly the incidence of suicidality and suicidal 
ideation. The safety profile of rimonabant was 
reviewed by the EMEA and its use in patients with 
ongoing major depressive illness and/or ongoing 
antidepressive treatment is now precluded. 
Scope of the ERG report
The ERG report presented a critical evaluation 
of the manufacturer’s submission (Sanofi-
Aventis), which evaluated the evidence for the 
clinical effectiveness, safety, tolerability and 
cost-effectiveness of rimonabant in its licensed 
indication as an adjunct to diet and exercise, 
relative to other licensed antiobesity drugs (orlistat 
and sibutramine) and diet and exercise alone. 
Methods 
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process. In addition, the ERG:
•  Generated tables from data provided in 
the body of the original and clarification 
submissions, and the appendices of the 
original submission, in order to present a clear 
summary of the relative and absolute weight 
effects of rimonabant at 1 year.
•  Repeated the meta-analyses for the primary 
weight loss outcomes [except for body mass 
index (BMI) as insufficient data were provided] 
including all four RIO trials (Rimonabant In 
Obesity).
•  Compared the results for orlistat and 
sibutramine included in the submission with 
those presented in the NICE guidelines3 
because of concerns about how representative 
of the general literature the trials of orlistat 
and sibutramine included in the submission 
were. 
•  Conducted additional analyses to provide 
further insight into the potential impact on the 
cost-effectiveness estimates of key issues and 
uncertainties identified during the structured 
critique of the manufacturer’s submission.
•  Conducted additional analyses to clarify the 
relative importance of the independent effect 
of BMI on utilities compared with the impact 
of the other risk factors on cardiovascular 
disease (CVD) and diabetes event rates in the 
incremental cost-effectiveness ratio (ICER) 
estimates.
Results 
Summary of submitted 
clinical evidence
Effectiveness of rimonabant
The evaluation of the efficacy of rimonabant 
focused primarily on the results of four Sanofi-
Aventis-sponsored randomised control trials 
(RCTs): (RIO-Europe4, RIO-North America5, 
RIO-Diabetes6 and RIO-Lipids7). Two further 
trials were cited but did not contribute to the main 
meta-analyses [SERENADE (Study Evaluating 
Rimonabant Efficacy in drug-NAive DiabEtic 
patients) and REBA (Riminobant Eating Behaviour 
Assessment study)]. Data from two unpublished 
studies were used to inform the analysis of adverse 
effects (EFC5745 and ACT3801). Rimonabant for the treatment of overweight and obese people
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Rimonabant resulted in a significantly greater 
benefit than placebo in terms of all primary weight 
loss outcomes:
•  change in weight (kg): non-diabetics: weighted 
mean difference (WMD) –4.91 [95% confidence 
interval (CI) –5.35 to –4.48]; diabetics: WMD 
–3.90 (95% CI –4.57 to –3.23)
•  proportion of patients losing 5% body weight: 
non-diabetics: relative risk (RR) 2.61 (95% CI 
2.32 to 2.95); diabetics: RR 3.41 (95% CI 2.58 
to 4.50)
•  proportion of patients losing 10% body weight: 
non-diabetics: RR 3.48 (95% CI 2.84 to 4.27); 
diabetics: RR 8.07 (95% CI 3.37 to 17.46)
•  change in waist circumference (cm): non-
diabetics: WMD –4.01 (95% CI –4.50 to –3.53); 
diabetics: WMD –3.30 (95% CI –4.17 to –2.43)
•  BMI (kg/m2): non-diabetics: WMD –1.76 (95% 
CI –1.92 to –1.60); diabetics: WMD –3.90 (95% 
CI –4.57 to –3.23); for any baseline BMI, the 
average weight loss beyond that which can be 
achieved with diet and exercise over a 1-year 
period is around 5 kg, with a fall in BMI of 
1.7 kg/m2.
The ERG generated pooled estimates using data 
from all four of the RIO trials. The results for 
the change in weight and the proportion who 
achieved 5% weight loss are shown in Figures 1 
and 2 respectively. These analyses show that the a 
priori decision by the manufacturer to pool data 
for diabetics and non-diabetics separately was 
justified statistically as well as clinically. However, 
although the mean weight loss and placebo-
subtracted reduction in BMI in the RIO-Diabetes 
trial were slightly lower than in the other RIO 
trials, the other primary outcomes did not indicate 
any materially different treatment effect in this 
population.
Two of the RIO trials (RIO-North America, RIO-
Lipids) reported significantly greater reductions 
in body weight in patients achieving at least 5% 
weight loss with rimonabant than with placebo. 
None of the trials reported significantly greater 
reductions in body weight in patients achieving at 
least 10% weight loss with rimonabant, or in waist 
circumference in patients achieving at least 5% or 
10% weight loss with rimonabant compared with 
placebo.
At 1 year, rimonabant had a statistically significant 
beneficial effect on systolic blood pressure, high-
density lipoprotein cholesterol, triglycerides and 
fasting plasma glucose in both diabetic and non-
diabetic patients, and glycosylated haemoglobin 
(HbA1c) in diabetic patients. Weight loss and 
improvements in associated cardiovascular and 
diabetes risk factors were maintained over 2 years 
when rimonabant was continued; however, the 
relative benefit over placebo was lower in year 2. 
Following withdrawal of rimonabant treatment at 
1 year, there was a gradual reduction in the rate 
of weight loss until there was no difference from 
placebo at 2 years.
In total, 13 adverse events were identified by the 
manufacturer as being associated with rimonabant 
at a rate of ≥ 2%, and at a rate of ≥ 1% greater 
than placebo (Table 1). Some form of psychiatric 
adverse event was experienced by 26% of patients 
receiving 20 mg rimonabant across the four RIO 
trials, compared with 14% of patients receiving 
placebo. Symptoms of depression were reported in 
9% of patients taking 20 mg rimonabant compared 
with 5% of patients taking placebo. These rates 
were broken down further, with the most commonly 
reported psychiatric adverse events as stated in the 
FDA briefing shown in Table 2.8
Two separate instruments were used to evaluate the 
effect of rimonabant on health-related quality of 
life (HRQoL). One was the obesity-specific Impact 
of Weight on Quality of Life-Lite (IWQOL-Lite) 
and the other the generic Medical Outcomes Study 
Short Form-36 (SF-36). Rimonabant provided 
benefits in some areas of HRQoL, particularly 
physical functioning, but was associated with a 
significant deterioration in mental health. 
On request, the manufacturer provided analyses 
of responder and non-responder data for 3, 6, 
9 and 12 months. These analyses were based on 
patients with complete weight measurements 
for months 3, 6 and 9. Data at 12 months were 
based on an intention-to-treat (ITT) analysis 
using last observation carried forward (LOCF). 
For rimonabant-treated patients, responders lost 
more weight than non-responders. Comparison of 
the 12-month response data based on the LOCF 
and completer analysis indicates the use of the 
completer analysis is likely to result in higher 
response rates than the LOCF approach (e.g. 
49.3% using LOCF compared with 64.4% using a 
completer analysis for one of the two populations 
considered, 49.4% versus 56% for the other).
In addition, the manufacturer provided an 
assessment of the diagnostic value of predicting a Health Technology Assessment 2009; Vol. 13: Suppl. 3
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1-year response at earlier time points by calculating 
the sensitivity and specificity of these time points. 
At 3 months sensitivity was 0.57 and specificity 
0.89; sensitivity increased at 6 and 9 months (0.85 
and 0.91 respectively) and specificity remained 
high (0.80 and 0.81 respectively). 
Comparison of rimonabant with 
orlistat and sibutramine
In the absence of head-to-head trials, the 
manufacturer provided tabulated comparisons 
between the placebo-subtracted results for 
orlistat, sibutramine and rimonabant. On request, 
pairwise comparisons between rimonabant and 
sibutramine and orlistat were provided for the 
primary outcomes. These pairwise comparisons 
showed a significant increase in the number of 
patients achieving 5% weight loss with rimonabant 
compared with sibutramine in the non-diabetic 
population. In addition, rimonabant compared 
favourably with orlistat in terms of body weight 
(non-diabetics, diabetics and dyslipidaemics); waist 
circumference (non-diabetics and dyslipidaemics); 
change in BMI (non-diabetics); patients who 
achieved 5% weight loss (non-diabetics and 
diabetics); and patients who achieved 10% weight 
loss (non-diabetics and diabetics). There was no 
comparison of adverse events or HRQoL between 
rimonabant and orlistat or sibutramine.
Summary of submitted 
cost-effectiveness evidence
Only one previously published study reporting on 
the cost-effectiveness of rimonabant was identified. 
This study evaluated the cost-effectiveness of 
rimonabant compared with diet and exercise 
Review:  Rimonabant
Comparison:  01 Rim 20  mg vs placebo
Outcome:  01 Change in weight kg
Study or 
sub-category N
Rimonabant
Mean (SD) N
Placebo
Mean (SD)
WMD (ﬁxed)
95% CI
Weight
%
WMD (ﬁxed)
95% CI
RIO–EU 595 −6.60 (7.20) 302 −1.80 (6.40) 15.65 −4.80 (−5.73 to −3.87)
RIO–NA 1189 −6.30 (7.10) 590 −1.60 (5.70) 35.77 −4.70 (−5.31 to −4.09)
RIO–diabetes 336 −5.30 (5.20) 345 −1.40 (3.60) 29.53 −3.90 (−4.57 to −3.23)
RIO–lipids 344 −6.90 (6.10) 334 −1.50 (5.00) 19.05 −5.40 (−6.24 to −4.56)
Total (95% CI) 2464 1571 100.00 −4.61 (−4.98 to −4.25)
Test for heterogeneity: χ
2 = 7.93, df = 3 (p = 0.05), I
2 = 62.1%
Test for overall effect z = 24.70 (p < 0.00001)
–10 –5 0 5 10
Favours placebo Favours rimonabant
Review:  Rimonabant
Comparison:  01 Rim 20  mg vs placebo
Outcome:  02 Proportion 5% weight loss
Study or 
sub-category
Rimonabant
n/N
Placebo
n/N
RR (ﬁxed)
95% CI
Weight
%
RR (ﬁxed)
95% CI
RIO–EU 303/595 58/302 21.98 2.65 (2.08 to 3.39)
RIO–NA 578/1189 118/590 45.05 2.43 (2.05 to 2.89)
RIO–diabetes 166/336 50/343 14.13 3.39 (2.57 to 4.48)
RIO–lipids 201/344 65/334 18.84 3.00 (2.37 to 3.80)
Total (95% CI) 2464 1569 100.00 2.72 (2.44 to 3.04)
Total events: 1248 (rimonabant), 291 (placebo)
Test for heterogeneity: χ
2 = 4.77, df = 3 (p = 0.19), I
2 = 37.1%
Test for overall effect z = 17.74 (p < 0.00001)
0.1 0.2 0.5 1 5 2 10
Favours placebo Favours rimonabant
FIGURE 1  Meta-analyses for change in weight (kg) from baseline to 1 year (intention to treat data) (ERG generated). CI, confidence 
interval; SD, standard deviation; WMD, weighted mean difference.
FIGURE 2  Proportion of patients achieving 5% weight loss. CI, confidence interval; RR, relative risk.Rimonabant for the treatment of overweight and obese people
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TABLE 1  The proportion of patients experiencing adverse events at a rate of ≥ 2% in the rimonabant group and ≥ 1% more than in the 
placebo group; results are pooled from seven trials for the 1-year data (the four RIO trials, REBA, EFC5745 and ACT3801) and two trials 
for the 2-year data (RIO-North America and RIO-Europe) 
Year 1 
Rimonabant (n = 2742) Placebo (n = 2474)
Any event 86.3 81.4
Nausea 13.6 4.7
Diarrhoea 7.7 5.8
Vomiting 4.7 2.3
Dizziness 7.3 4.1
Anxiety 5.9 2.1
Insomnia 5.8 3.4
Mood alterations with depressive symptoms 4.7 2.8
Depressive disorders 3.9 1.7
Influenza 10.3 9.1
Asthenia/fatigue 6.1 4.4
Gastroenteritis 4.5 3.5
Contusion 3.1 1.1
Hot flush 2 0.8
TABLE 2  The number (%) of patients experiencing psychiatric symptoms across the four RIO trials as reported in the US Food and Drugs 
Administration briefing document8
20 mg rimonabant Placebo
Any psychiatric adverse event 569 (26.2) 226 (14.1)
Anxiety 131 (6.02) 40 (2.50)
Insomnia 118 (5.42) 53 (3.31)
Depressed mood 83 (3.81) 45 (2.81)
Depression 74 (3.40) 23 (1.44)
Irritability 1.93% 0.56%
Stress 38 (1.75) 28 (1.75)
Nervousness 31 (1.42) 5 (0.31)
Depressive symptoms 23 (1.06) 12 (0.75)
Sleep disorder 21 (0.97) 7 (0.44)
Nightmare 21 (0.97) 3 (0.19)
alone. No published studies were identified that 
had compared rimonabant with other licensed 
antiobesity drugs. 
The manufacturer’s submission was based on a de 
novo economic evaluation of rimonabant compared 
with orlistat, sibutramine and diet and exercise 
alone. Separate models were presented based on a 
Markov cohort model and a patient-level approach 
using discrete event simulation. The main 
submission focused on the Markov cohort model. 
The Markov model evaluated the following 
treatment comparisons: (1) lifetime rimonabant 
plus diet and exercise versus lifetime diet and 
exercise alone; (2) lifetime rimonabant plus diet 
and exercise versus lifetime orlistat plus diet and 
exercise; and (3) 1-year rimonabant plus diet and 
exercise versus 1-year sibutramine plus diet and 
exercise. The results of the economic evaluation 
were presented for three base-case populations: (1) 
overweight or obese patients with treated type 2 
diabetes (diabetic group); (2) overweight or obese 
patients with dyslipidaemia, not treated with a 
statin and without type 2 diabetes (dyslipidaemic Health Technology Assessment 2009; Vol. 13: Suppl. 3
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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group); and (3) obese patients with or without 
comorbidities (obese group). A number of 
additional subgroups were considered as part of the 
sensitivity analysis.
In the absence of direct head-to-head RCT data 
for the alternative strategies, indirect approaches 
were employed to assess the relative effectiveness 
of each treatment strategy in terms of its impact 
on a number of established risk factors for CVD 
and diabetes. A series of published risk equations 
was used to translate changes in these risk factors 
to a reduced risk of CVD and, in patients without 
diabetes, to a reduced risk of developing diabetes. 
The effect of the treatments on BMI was also 
assumed independently to influence HRQoL 
beyond that attributed to the effect on CVD and 
diabetes risks. These approaches were used as 
the basis for estimating quality-adjusted life-years 
(QALYs) over a lifetime time horizon. Costs were 
based on the drug acquisition and monitoring 
costs, adverse events and the costs of CVD and 
diabetes. Costs and QALYs were compared and 
ICERs of rimonabant estimated when appropriate. 
The robustness of the results was assessed using 
deterministic and probabilistic sensitivity analyses.
Across the base-case populations, the ICER of 
rimonabant varied from £10,534 to £13,236 per 
QALY versus diet and exercise, from £8977 to 
£12,138 per QALY versus orlistat and from £1463 
to £3908 per QALY versus sibutramine. In the 
additional subgroups considered there was a wider 
variation in the ICER estimates; however, none 
of the individual pairwise ICERs for rimonabant 
exceeded £20,000 per QALY in any of the 
subgroups. The ICER estimates across the majority 
of the sensitivity analyses were broadly consistent 
with the base-case results. 
The ERG considered that the original submission 
contained a number of important uncertainties and 
issues which potentially compromised the validity 
of the model results. A number of these issues 
were addressed by the manufacturer as part of 
their response to the ERG’s points for clarification. 
The ERG identified a number of remaining 
issues related to the manufacturer’s response and 
several of these were subsequently addressed with 
additional analyses conducted by the ERG. The 
ICER of rimonabant remained relatively robust 
throughout the reanalyses by the manufacturer 
and the ERG (< £20,000 per QALY), although 
the results did appear to be sensitive to the source 
of HRQoL benefits assumed in the model, with 
markedly less favourable ICER estimates using data 
from the RIO trials. However, the ERG considered 
that several important caveats and uncertainties 
remained.
On request, the manufacturer provided 
comparisons of rimonabant versus diet and 
exercise alone and orlistat and sibutramine; in each 
analysis, four treatment strategies were modelled 
in which treatment with rimonabant was continued 
only in patients achieving 5% weight loss at 3, 6, 9 
or 12 months. Further modifications to the model 
included: discontinuation of treatment when a 
patient returned to their original weight while 
on treatment; a disutility for depressive adverse 
events associated with rimonabant; inclusion of 
costs of screening/monitoring for depression for 
patients treated with rimonabant; and long-term 
deterioration of efficacy of all treatments after 1 
year.
Compared with diet and exercise alone, the 
response hurdles for rimonabant of between 6 
and 9 months were demonstrated to be more 
cost-effective than a response hurdle of 3 months 
in the analyses of overweight or obese patients 
with diabetes and obese patients with or without 
risk factors. When compared with orlistat and 
sibutramine, the ICER of rimonabant employing a 
6-month response hurdle was £30,743 per QALY 
compared with a 3-month response hurdle for 
sibutramine for overweight or obese patients with 
diabetes, and £23,644 per QALY for obese patients 
with or without risk factors. 
Pairwise comparisons were presented, showing the 
upper and lower ICERs for rimonabant versus the 
three comparators. Rimonabant was reported to 
remain below a threshold of £30,000 per QALY in 
70% of the pairwise comparisons reported. The 
results appeared most sensitive to the decrement 
applied to depression and the costs of screening for 
depression.
Commentary on 
the robustness of 
submitted evidence
Strengths
The manufacturer’s submission presented a clear 
overview of the four major trials (RIO trials4–7) 
conducted with rimonabant in overweight or obese 
patients with data for up to 2 years. The submission 
also included a comparison with the appropriate 
comparators orlistat and sibutramine. 
The manufacturer used appropriate criteria to 
assess the quality of the RIO trials, although Rimonabant for the treatment of overweight and obese people
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the ERG noted some discrepancies between the 
assessments provided in the submission and the 
information available in published trial reports. 
The ERG assumes that the manufacturer had 
access to the full trial reports.
The manufacturer’s submission was considered 
to comprise the most relevant source of cost-
effectiveness evidence relating to the use of 
rimonabant. The ERG identified a number of 
strengths in the manufacturer’s cost-effectiveness 
analysis. The overall model structure, approaches 
to estimating long-term costs and outcomes 
(expressed using QALYs), the time horizon 
employed and the approach to handling parameter 
uncertainty were all consistent with the NICE 
reference case for cost-effectiveness analysis. 
The ERG also noted that the manufacturer had 
compared rimonabant against other licensed 
antiobesity drugs as well as against diet and 
exercise alone. A broad range of sensitivity 
analyses was also undertaken to explore alternative 
assumptions. Variation in the cost-effectiveness 
estimates for rimonabant was considered in a 
number of different patient subgroups. The ERG 
also felt that the validation approaches employed 
by the company (including presenting the results 
of a separate discrete event simulation) were a 
relative strength of the submission. Finally, the 
ERG felt that the manufacturer had attempted to 
address a number of areas of uncertainty identified 
by the ERG in their response to the points for 
clarification. 
In general, the ERG felt that the revised 
submission provided by the manufacturer had 
adequately addressed the main clarification 
points raised. The ERG noted that several of the 
assumptions employed by the manufacturer to 
address these points were conservative towards 
rimonabant; however, a more limited range of 
subgroups was considered in the resubmission – 
data on overweight and obese patients with risk 
factors other than diabetes were omitted.
Weaknesses
The four included trials may not be generalisable 
to the UK population, both in terms of baseline 
BMI and the differences in lifestyle, diet and 
attitudes towards alcohol consumption and exercise 
between the UK and the USA and other European 
countries. Furthermore, the diabetic patients 
included in the manufacturer’s submission did 
not include insulin-dependant diabetics and so 
may not be generalisable to the broader diabetic 
population. 
The comparison of the effects of rimonabant with 
those of orlistat and sibutramine on weight loss 
outcomes is uncertain given the differences in diet 
and exercise that might have been employed across 
the different trials. There was no comparison of 
2-year data between rimonabant and orlistat. There 
are differences in the licensing of rimonabant 
compared with that of orlistat and sibutramine; 
orlistat and sibutramine are subject to response 
‘hurdles’ in practice that may not be applied in 
trials and therefore any additional benefit of 
rimonabant over orlistat or sibutramine may be 
overestimated and may not be apparent in normal 
clinical practice.
Overall, the ERG found the presentation of the 
data unclear, particularly that for orlistat and 
sibutramine. The ERG has concerns over how 
representative of the general literature the trials of 
orlistat and sibutramine in the submission are, and 
how objectively the data have been used.
The ERG identified a number of potential 
weaknesses in the manufacturer’s cost-effectiveness 
analysis. The most significant was considered to be 
the lack of response hurdles applied to sibutramine 
and orlistat, such that the comparator strategies 
were not considered by the ERG to reflect their 
respective product licenses or current NHS use. 
Although this issue was partially addressed by 
the manufacturer in the response to the ERG 
points for clarification, the ERG did not consider 
that this aspect had been robustly considered 
by the manufacturer and hence it represents 
a major limitation. The revised submission by 
the manufacturer addressed this issue further. 
However, there remained potential inconsistency 
in the approaches used to estimate the response 
rates for the alternative time points representing 
continuation hurdles for rimonabant; at 3, 6, 
and 9 months completer data were used and at 
12 months LOCF was used. Although the ERG 
recognises that the manufacturer presented a more 
consistent approach as part of their clarification, 
the ERG considers that the full ITT LOCF would 
represent a more conservative approach and that 
the current analyses may overstate the response 
rates at 3, 6 and 9 months. In addition, there was 
a lack of conditional response data for sibutramine 
and orlistat (the change in individual risk factors 
for responders and non-responders) resulting in 
the use of different approaches to estimate the 
cost-effectiveness of rimonabant versus diet and 
exercise alone (patient-level data from the RIO 
trials) and versus orlistat and sibutramine [applying 
the average change in risk factors reported for the 
active treatments (regardless of response status) to Health Technology Assessment 2009; Vol. 13: Suppl. 3
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responders, and the average change in risk factors 
for diet and exercise to non-responders].
The ERG also considered the manufacturer’s 
approach to evaluating HRQoL benefits to be 
subject to a number of important uncertainties. 
The ERG considered that the manufacturer’s 
reliance on external utility estimates, as opposed 
to the HRQoL data reported in the RIO trials, 
was a potential weakness. Indeed, the HRQoL 
benefits associated with rimonabant remain highly 
uncertain and need more detailed investigation by 
the manufacturer.
Conclusions 
Key issues 
The adequacy of the cost-effectiveness modelling 
and assumptions regarding strategies utilising 
response hurdles for rimonabant and comparator 
treatments is a key concern. Also, the use of 
external evidence on the HRQoL impact of BMI 
independent of longer-term clinical events rather 
than estimates from the trials, and the choice of 
this external evidence, are key issues.
The lack of evidence on the effect of rimonabant 
on ‘hard’ end points, such as CVD, diabetes 
and mortality, is a major limitation. Data are 
also lacking on the effectiveness and safety of 
rimonabant beyond 2 years. In addition, the 
appropriateness of incorporating the link between 
BMI reductions and a lower risk of diabetes and 
CVD and the choice of evidence to inform this link 
are questionable.
There are concerns over the psychiatric morbidity 
associated with rimonabant and, given the 
lack of long-term data, the cumulative data on 
less common side-effects are uncertain. The 
generalisability to the UK overweight and obese 
population is uncertain, particularly in the broader 
diabetic population as there are no data on the 
effectiveness or safety of rimonabant in insulin-
dependant diabetics.
Areas of uncertainty
Areas of uncertainty remain in relation to the 
clinical effectiveness and safety of rimonabant. A 
major area where data are lacking relates to the 
long-term outcomes, with no effectiveness or safety 
data presented for rimonabant beyond 2 years 
and limited data available beyond 1 year. Also, the 
manufacturer has identified no direct evidence 
for the effect of rimonabant on hard clinical end 
points, such as cardiovascular events, developing 
diabetes and mortality. The manufacturer states 
that results from an ongoing trial, CRESCENDO 
(Comprehensive Rimonabant Evaluation Study 
of Cardiovascular Endpoints and Outcomes), 
which is evaluating the effect of rimonabant 
on cardiovascular morbidity and mortality, are 
expected to be available in 2011. 
Given the lack of head-to-head comparisons 
between rimonabant and orlistat or sibutramine 
with all three drugs given as per license, it is 
unclear whether the pairwise comparisons 
between rimonabant and orlistat and sibutramine, 
presented in the clarification submission, will 
reflect that seen in clinical practice; response 
hurdles imposed on orlistat or sibutramine in 
clinical practice may not have been applied in the 
orlistat and sibutramine trials. 
With respect to cost-effectiveness, a number of 
issues and uncertainties were addressed by the 
manufacturer in their response to the ERG’s 
points for clarification. Some remaining issues 
relating to the manufacturer’s response were 
subsequently addressed with additional analyses 
conducted by the ERG and a revised submission 
by the manufacturer. However, some caveats and 
uncertainties remain with respect to the modelling 
of the comparator technologies and the HRQoL 
benefits associated with rimonabant. 
Summary of NICE guidance 
issued as a result of the STA 
The guidance issued by NICE in March 2008 states 
that: 
Rimonabant, within its licensed indications, is 
recommended as an adjunct to diet and exercise 
for adults who are obese or overweight and 
who have had an inadequate response to, are 
intolerant of or are contraindicated to orlistat and 
sibutramine. 
Rimonabant treatment should be continued 
beyond 6 months only if the person has lost at 
least 5% of their initial body weight since starting 
rimonabant treatment. 
Rimonabant treatment should be discontinued if 
a person returns to their original weight while on 
rimonabant treatment. Rimonabant for the treatment of overweight and obese people
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Rimonabant treatment should not be continued 
for longer than 2 years without a formal clinical 
assessment and discussion of the individual risks 
and benefits with the person receiving treatment.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of telbivudine 
for the treatment of chronic hepatitis B (CHB) in 
adults based upon a review of the manufacturer’s 
submission to the National Institute for Health 
and Clinical Excellence (NICE) as part of the 
single technology appraisal (STA) process. The 
submission’s evidence came from one randomised 
controlled trial (RCT) (GLOBE) of reasonable 
methodological quality comparing telbivudine 
with lamivudine. One other RCT that appeared 
to meet the inclusion criteria was excluded from 
the submission. For the primary outcome of 
therapeutic response telbivudine was statistically 
superior to lamivudine at weeks 52 and 104 for 
hepatitis B e antigen (HBeAg)-positive patients, 
and at week 104 for HBeAg-negative patients. 
There were statistically significant differences in 
favour of telbivudine for some secondary outcomes 
at 2 years including hepatitis B virus (HBV) 
DNA reduction, HBV DNA non-detectability and 
alanine aminotransferase normalisation though 
not for HBeAg-positive patients. In HBeAg-
positive patients there was no significant difference 
between treatment groups for HBeAg loss or 
seroconversion at any time point. The incidence 
of adverse events was similar between treatments. 
Two RCTs comparing entecavir with lamivudine 
were included in the indirect comparison; however, 
this was poorly conducted and the results should 
be treated with caution. The manufacturer 
developed two economic models to determine the 
cost-effectiveness of telbivudine. Evidence on the 
efficacy of telbivudine and lamivudine was taken 
from the GLOBE trial; efficacy of adefovir was 
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based on assumption. There was a lack of critical 
assessment and assurance of the quality of the data 
used to populate the models. The manufacturer 
concluded that telbivudine is a cost-effective option 
compared with lamivudine using evidence from 
the viral load model [HBeAg-positive patients/
HBeAg-negative patients: mean incremental 
cost £19,087/£49,003, mean quality-adjusted 
life-year (QALY) gain 1.30/4.67, incremental 
cost-effectiveness ratio (ICER) £14,665/£10,497 
per QALY]. Resubmitted results after a request 
for clarification by the ERG gave less favourable 
ICERs (HBeAg-positive patients/HBeAg-negative 
patients: mean incremental cost £23,983/£41,910, 
mean QALY gain 1.56/2.07, ICER £15,377/£20,256 
per QALY). The manufacturer concluded that 
telbivudine is a cost-effective option (on its own 
or followed by adefovir) for patients who have 
developed resistance to first-line telbivudine 
treatment; however, the presentation of the results 
was not ideal. In conclusion, although telbivudine 
was statistically superior to lamivudine for most 
antiviral outcomes, the difference was not clinically 
significant; in addition, the cost-effectiveness 
evidence for telbivudine presented in the 
manufacturer’s submission was limited. The NICE 
guidance issued as a result of the STA states that 
telbivudine is not recommended for the treatment 
of chronic hepatitis B and that people currently 
receiving telbivudine should have the option to 
continue therapy until they and their clinicians 
consider it appropriate to stop.
Introduction 
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
of the clinical effectiveness and cost-effectiveness of 
telbivudine for the treatment of chronic hepatitis B 
(CHB) in adults.
Description of the 
underlying health problem
Hepatitis B is an infectious disease of the liver 
caused by the hepatitis B virus (HBV). The majority 
of people who are infected as adults recover 
spontaneously, but around 5% develop CHB, 
defined as viraemia and hepatic inflammation for 
more than 6 months.2 If not successfully treated 
it can lead to progressive liver damage, including 
cirrhosis, hepatocellular carcinoma (HCC) and 
death. Patients with CHB may be hepatitis B e 
antigen (HBeAg) positive or HBeAg negative, 
depending on the presence or absence of the ‘e’ 
antigen.
The Department of Health2 and the British Liver 
Trust3 estimate that the prevalence of CHB in 
the UK is approximately 150,000–200,000, with 
around 7000 estimated new cases every year 
(mostly from immigration of established HBV 
carriers). However, the Hepatitis B Foundation4 
recently estimated that prevalence may have 
increased to 325,000, and it is thought likely to 
increase further as a consequence of increasing 
rates of immigration of people from countries with 
a high CHB prevalence.
The main goal of antiviral therapy is to suppress 
the level of the virus (HBV DNA) for a prolonged 
period of time to reduce the risk of disease 
progression and HCC, and also to improve long-
term outcomes. HBV DNA is one of the key 
markers of disease management, as well as HBeAg 
seroconversion, alanine aminotransferase (ALT) 
levels and, over the longer term, histological 
response.
Scope of the ERG report
The ERG critically evaluated the evidence 
submission from Novartis for the use of telbivudine 
for the treatment of CHB, in accordance with 
the licensed indication. Telbivudine is a synthetic 
thymidine nucleoside analogue that inhibits HBV 
DNA polymerase and thus HBV replication. It is 
licensed for the treatment of CHB in adult patients 
with compensated liver disease and evidence 
of viral replication, persistently elevated serum Health Technology Assessment 2009; Vol. 13: Suppl. 3
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ALT levels and histological evidence of active 
inflammation and/or fibrosis.
The outcomes stated in the manufacturer’s 
definition of the decision problem were HBV 
DNA virological response, seroconversion rate, 
histological improvement, biochemical response, 
viral resistance, time to treatment failure, survival, 
health-related quality of life and adverse effects.
Methods 
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process. 
The ERG checked the literature searches and 
applied the NICE critical appraisal checklist to 
the included studies and checked the quality of 
the manufacturer’s submission with the Centre 
for Reviews and Dissemination (CRD) quality 
assessment criteria for a systematic review. 
In addition, the ERG checked and provided 
commentary on the manufacturer’s model using 
standard checklists. A one-way sensitivity analysis, 
scenario analysis and a probabilistic sensitivity 
analysis (Figures 1 and 2) were undertaken by the 
ERG.
Results 
Summary of submitted 
clinical evidence
The manufacturer’s submission presented 
clinical evidence for telbivudine in patients with 
compensated CHB based on one multicentre, 
international, double-blind randomised controlled 
trial (RCT) (the GLOBE trial).5 This was the 
pivotal registration trial for telbivudine. The trial 
compared telbivudine with lamivudine in patients 
with HBeAg-positive and HBeAg-negative CHB for 
104 weeks. The 2-year data presented throughout 
the manufacturer’s submission are unpublished, 
although publications of earlier results from the 
GLOBE trial are available. 
For the primary outcome of therapeutic response 
(suppression of HBV DNA < 5 log copies/ml plus 
either clearance of detectable HBeAg or ALT 
normalisation) telbivudine was statistically superior 
to lamivudine at weeks 52 and 104 for HBeAg-
positive patients, and at week 104 for HBeAg-
negative patients.
In terms of secondary outcomes there were 
statistically significant differences in favour of 
telbivudine for HBV DNA reduction, HBV DNA 
non-detectability, ALT normalisation (although 
not for HBeAg-negative patients), virological 
breakthrough and HBV resistance at 2 years. In 
HBeAg-positive patients there was no significant 
difference between treatment groups for HBeAg 
loss or seroconversion at any time point. There 
were no significant differences in histological 
response or change in fibrosis score at 1 year, 
with the exception of histological improvement 
in HBeAg-positive patients, which was greater in 
telbivudine patients than in lamivudine patients. 
In terms of adverse events there appeared to be no 
difference between treatments.
In the elevated ALT subset analysis of the HBeAg-
positive subgroup, telbivudine was statistically 
superior to lamivudine for most outcomes. In 
the ethnicity subgroup analysis, telbivudine was 
significantly more favourable than lamivudine 
in Asian patients, but there were no statistically 
significant differences between treatments for 
HBeAg-positive Caucasian patients and few 
differences for HBeAg-negative Caucasian patients.
Two RCTs comparing entecavir with lamivudine 
were included in the indirect comparison, one 
in HBeAg-positive patients6 and one in HBeAg-
negative patients.7 In the indirect comparison 
of telbivudine and entecavir, the manufacturer’s 
submission reported that there were no statistically 
significant differences for any efficacy outcome.
Summary of submitted cost-
effectiveness evidence
The manufacturer’s submission presented evidence 
on the cost-effectiveness of telbivudine using two 
economic models, referred to as the viral load and 
seroconversion models. Evidence on the efficacy of 
telbivudine and lamivudine, in terms of reducing 
viral load, the probability of normalising ALT 
and HBeAg seroconversion, was taken from the 
GLOBE trial for a subgroup of patients with ALT 
levels ≥ two times the upper limit of normal (ULN). 
The benefit of these outcomes is that they are 
associated with reduced probability of progression 
to advanced liver disease. Efficacy of adefovir was 
based on assumption.
The viral load model, the manufacturer’s preferred 
approach, stratified response to treatment and Telbivudine for the treatment of chronichepatitis B infection 
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FIGURE 1  CEACs from ERG probabilistic analysis using viral load model. a, CEAC for telbivudine compared with lamivudine (HBeAg-
positive cohort – prior =0); b, CEAC for telbivudine compared with lamivudine (HBeAg-negative cohort – prior = 0). CEAC, cost-effectiveness 
acceptability curve; ERG, evidence review group; HBeAg, hepatitis B e antigen; QALY, quality-adjusted life-year.
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the development of resistance by five viral load 
levels and regarded reducing viral load as a key 
determinant of disease progression. This model 
is relevant both to patients with HBeAg-positive 
CHB and to those with HBeAg-negative CHB. 
The viral load model incorporated a multivariate 
risk model to derive transition probabilities for 
the development of progressive liver disease 
based on viral load levels, the probability of ALT 
normalisation and HBeAg serological status (for 
HBeAg-positive patients). Two versions of the viral 
load model were submitted. The first used the 
observed proportion of patients moving between 
states to estimate transition probabilities (referred 
to as ‘zero prior’). In the second model an arbitrary 
value of 0.5 was added to all numerators and 
denominators (referred to as ‘0.5 prior’).
The seroconversion model was an attempt to 
replicate the model used in a recent NICE 
assessment2 and was structured with HBeAg 
seroconversion as the key determinant of disease 
progression. By definition this model is relevant 
only to patients with HBeAg-positive CHB.
Both models adopted a lifetime horizon and 
extrapolated lifetime costs and quality-adjusted life-
years (QALYs) for patients treated with telbivudine 
and each of the included comparators. Incremental 
cost-effectiveness ratios (ICERs) were estimated 
against different comparators (depending on the 
model used) in the manufacturer’s submission. The 
comparator in the viral load model was lamivudine, 
whereas in the seroconversion model there were 
multiple competing interventions (lamivudine, 
telbivudine and adefovir alone or in sequence 
as well as best supportive care). All ICERs in the 
seroconversion model were calculated relative to 
best supportive care.
The manufacturer’s submission concluded that 
telbivudine is a cost-effective option compared 
with lamivudine using evidence from the viral load 
model (mean incremental cost of £19,087, mean 
QALY gain of 1.30 with an ICER of £14,665 per 
QALY gained for HBeAg-positive patients and 
mean incremental cost of £49,003, mean QALY 
gain of 4.67 with an ICER of £10,497 per QALY 
gained for HBeAg-negative patients). In response 
to a request for clarification from the ERG the 
manufacturer noted that there were errors in the 
models originally submitted and therefore in the 
results reported in the submission. Resubmitted 
results gave less favourable ICERs, particularly for 
HBeAg-negative patients (mean incremental cost 
of £23,983, mean QALY gain of 1.56 with an ICER 
of £15,377 per QALY gained for HBeAg-positive 
patients and mean incremental cost of £41,910,  Cactus Design and Illustration Ltd
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FIGURE 2  Cost-effectiveness frontier from seroconversion model (ERG’s probabilistic sensitivity analysis). BSC, best supportive care; ERG, 
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mean QALY gain of 2.07 with an ICER of £20,256 
per QALY gained for HBeAg-negative patients).
The manufacturer’s submission concluded that 
telbivudine is a cost-effective option – on its own 
or followed by adefovir – for patients who have 
developed resistance to first-line telbivudine 
treatment. The manufacturer’s submission reported 
ICERs for seven treatment strategies relative to best 
supportive care. This is not an ideal presentation 
of the results of competing treatment strategies. 
The ERG derived appropriate comparisons, 
based on the manufacturer’s results, using the 
cost-effectiveness frontier, estimating ICERs of 
£7887, £19,680 and £24,277 per QALY gained for 
lamivudine, telbivudine and telbivudine followed 
by adefovir respectively. The sequence of treatment 
options implied is problematic as the strategy 
of using telbivudine followed by adefovir (for 
patients who develop resistance to telbivudine) is 
not accessible to patients who have lamivudine as 
their first-line treatment. To provide the treatment 
strategy of telbivudine followed by adefovir 
(which yields the greatest QALY gain of all of the 
strategies in the seroconversion model and which 
is optimal at a willingness to pay greater than 
£25,000 per QALY) telbivudine must be available 
as a first-line treatment.
Commentary on 
the robustness of 
submitted evidence
Strengths
The manufacturer conducted a systematic search 
for clinical effectiveness studies of telbivudine. It 
appears unlikely that any additional trials would 
have met the inclusion criteria had the search been 
widened to include other databases.
The GLOBE trial appears to be of reasonable 
methodological quality (with some limitations) 
and measured a range of outcomes that are as 
appropriate and clinically relevant as possible, 
although health-related quality of life was not 
reported. On the whole, the manufacturer’s 
submission appears to represent an unbiased 
estimate of the antiviral treatment effect of 
telbivudine based on the results of one trial.
The methods adopted for the economic evaluation 
of telbivudine were broadly consistent with those 
adopted for previous evaluations of antiviral 
treatment of CHB, including the recent NICE 
assessment of adefovir and pegylated interferon.2
Weaknesses
The manufacturer’s submission did not include all 
of the comparators specified in the scope.
Despite a systematic search and screen of the 
literature, only one RCT was included. The 
manufacturer’s submission is therefore largely 
dependent upon this one trial. Further high-quality 
RCT evidence for the effectiveness of telbivudine in 
the patient group meeting the licensed indication 
would be beneficial.
Literature searches were poorly documented, 
lacking clarity and transparency throughout. 
Search filters were extremely precise at the 
expense of sensitivity. The processes undertaken 
by the manufacturer for data extraction and 
applying quality criteria to the GLOBE trial were 
not detailed and no formal quality assessment 
was undertaken on the comparator trials. These 
factors limit the robustness of the systematic 
review. In addition, one RCT8 that appeared to 
meet the inclusion criteria was excluded from the 
submission.
The indirect comparison with entecavir was poorly 
conducted and should be treated with caution. It 
was reported as a visual comparison and then as 
a statistical comparison, which the manufacturer 
deemed invalid. An inadequate description of the 
methodology was provided and the conclusions 
are based largely on a visual comparison of efficacy 
outcomes.
The economic models used data from a subgroup 
of patients in the GLOBE study and these data 
were not presented in detail in the clinical 
evidence section of the manufacturer’s submission. 
No information was given on the baseline 
characteristics of the subgroup of patients with ALT 
levels ≥ two times the ULN.
In the cost-effectiveness section of the submission 
the manufacturer paid insufficient attention to 
appraising the data used to populate the economic 
models. Denominators used for calculation of some 
transition probabilities appear inconsistent and 
some input values (e.g. resistance rates calculated 
using data reported in appendices) are substantially 
lower than those reported for all patients in the 
GLOBE study. These discrepancies were not 
discussed in the submission.
The electronic models submitted are complex and 
highly reliant on Visual Basic programming to Health Technology Assessment 2009; Vol. 13: Suppl. 3
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produce any analyses. There is a large amount of 
reprocessing of data within the models that was not 
clearly documented or readily apparent to the user.
There was little discussion in the manufacturer’s 
submission of uncertainty around the mean 
estimates reported as the base case for both 
the viral load and seroconversion models. The 
NICE guide to methods of technology appraisal 
describes confidence ellipses and scatter plots on 
the cost-effectiveness plane and cost-effectiveness 
acceptability curves as the most appropriate 
ways of presenting uncertainty in probabilistic 
sensitivity analysis. These were not presented for 
all comparisons and were submitted in appendices, 
without commentary, rather than in the main body 
of the report.
Conclusions 
Areas of uncertainty
The results of the key efficacy outcomes were 
broken down by HBeAg status, study treatment and 
(1) race/ethnicity or (2) ALT levels. It is not clear 
whether the GLOBE study was powered to detect 
differences in these subgroups. Without confidence 
intervals and standard deviations in the reporting 
of the results it is not possible to ascertain how 
much variance there was among the subgroups/
patients.
The rates of viral resistance to entecavir were not 
reported in the manufacturer’s submission and 
therefore do not allow for a comparison with the 
resistance rates for telbivudine.
The adjustments to the Cox proportional 
hazards models used to estimate the probability 
of developing compensated cirrhosis and HCC 
were inadequately reported as was the process of 
recalibration. These values enter the viral model 
deterministically – there is no assessment of 
parameter uncertainty for the risk models used 
in the viral model, nor of the methodological 
uncertainty around the adjustment or recalibration.
The lack of quality assurance of input data for 
both models introduces uncertainty – the impact 
of the prior value (zero or 0.5) on the model 
outcomes suggests that sparsity of data may be a 
problem, particularly for the model of HBeAg-
negative patients. This is not surprising, given that 
data on around 250 patients were stratified across 
viral load levels, ALT and serological status. The 
manufacturer’s submission contained no discussion 
of alternative modelling strategies that might 
reduce the impact of sparsity of data nor did it 
clearly indicate which input variables were most 
affected by differences in prior values.
Key issues 
Although telbivudine was statistically superior 
to lamivudine for most antiviral outcomes, the 
difference was not clinically significant, having 
an effectiveness advantage of only about 2% in 
patients treated between the two drugs. Viral 
breakthrough (> 1 log increase over nadir) for 
telbivudine was 28.6% at 2 years; although this 
is significantly lower than that for lamivudine 
(45.5%), the ERG’s clinical advisor asserts that it is 
still high in clinical terms.
The conclusions from the indirect comparison were 
based largely on a visual comparison of efficacy 
outcomes and a statistical indirect comparison, 
which the manufacturer’s submission states was 
not considered valid in the absence of any meta-
analyses. Telbivudine seems to have approximately 
the same efficacy as entecavir for viral suppression, 
but markedly higher rates of viral resistance (as per 
the rates for entecavir reported in the published 
trials). 
The exclusion of entecavir from all of the economic 
models and the restricted comparison included 
in the viral load model – telbivudine versus 
lamivudine, with no follow-up antiviral treatments 
– means that the cost-effectiveness evidence for 
telbivudine presented in the manufacturer’s 
submission is limited. Lack of critical assessment 
and assurance of the quality of the data used to 
populate the model (apparent inconsistencies and 
incomplete data for lamivudine and telbivudine 
from the GLOBE trial along with the absence 
of systematic searches for evidence on the 
comparative effectiveness of adefovir) further 
limits the evidence reported in the manufacturer’s 
submission.
Summary of NICE guidance 
issued as a result of the STA 
NICE guidance, published August 2008,9 states 
that:
1.1  Telbivudine is not recommended for the 
treatment of chronic hepatitis B.Telbivudine for the treatment of chronichepatitis B infection 
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1.2  People currently receiving telbivudine should 
have the option to continue therapy until they and 
their clinicians consider it appropriate to stop.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical and 
cost-effectiveness of entecavir for the treatment 
of chronic hepatitis B (CHB) in adults based 
upon a review of the manufacturer’s submission 
to the National Institute for Health and Clinical 
Excellence (NICE) as part of the single technology 
appraisal (STA) process. The submission’s 
evidence came from five randomised controlled 
trials (RCTs), of good methodological quality and 
measuring a range of clinically relevant outcomes, 
comparing entecavir with lamivudine. After 1 year 
of treatment entecavir was statistically superior 
to lamivudine in terms of the proportion of 
patients achieving hepatitis B virus (HBV) DNA 
suppression, alanine aminotransferase (ALT) 
normalisation and histological improvement, but 
not in terms of the proportion of patients achieving 
hepatitis B e antigen (HBeAg) seroconversion. 
The incidence of adverse or serious adverse events 
was similar for both treatments. The results of 
the manufacturer’s mixed treatment comparison 
(MTC) model to compare entecavir with the 
comparator drugs in nucleoside-naive patients were 
considered to be uncertain because of concerns 
over its conduct and reporting. For the economic 
evaluation the manufacturer constructed two 
Markov state transition models, one in HBeAg-
positive and one in HBeAg-negative patients. The 
modelling approach was considered reasonable 
subject to some uncertainties and concerns over 
some of the structural assumptions. In HBeAg-
positive patients the base-case incremental cost-
effectiveness ratios (ICER) for entecavir compared 
with lamivudine and pegylated interferon alpha-2a 
were £14,329 and £8403 per quality-adjusted life-
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year (QALY) respectively. Entecavir was dominated 
by telbivudine. In HBeAg-negative patients the 
base-case ICERs for entecavir compared with 
lamivudine, pegylated interferon alpha-2a and 
telbivudine were £13,208, £7511 and £6907 per 
QALY respectively. In HBeAg-positive lamivudine-
refractory patients entecavir dominated adefovir 
added to lamivudine. In one-way deterministic 
sensitivity analysis on all key input parameters for 
entecavir compared with lamivudine in nucleoside-
naive patients, ICERs generally remained under 
£30,000 per QALY. In probabilistic sensitivity 
analysis in nucleoside-naive HBeAg-positive 
patients the probability of the ICER for entecavir 
being below £20,000 per QALY was 57%, 82% 
and 45% compared with lamivudine, pegylated 
interferon alpha-2a and telbivudine respectively. 
In nucleoside-naive HBeAg-negative patients the 
probabilities were 90%, 100% and 96% respectively. 
The manufacturer’s lifetime treatment scenario for 
HBeAg-negative patients and the ERG’s 20-year 
treatment scenario for HBeAg-positive patients 
increased the ICERs, particularly in the latter 
case. Amending the HBeAg-negative model so 
that patients with compensated cirrhosis would 
also receive lifetime treatment gave probabilities 
of entecavir being cost-effective at a willingness 
to pay of £20,000 and £30,000 of 4% and 40% 
respectively. The NICE guidance issued in August 
2008 as a result of the STA states that entecavir is 
recommended as an option for the treatment of 
people with chronic HBeAg-positive or HBeAg-
negative hepatitis B in whom antiviral treatment is 
indicated.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
of entecavir for the treatment of chronic hepatitis B 
(CHB).
Description of the 
underlying health problem
Hepatitis B is an infectious disease of the liver 
caused by the hepatitis B virus (HBV). It is 
transmitted through blood-to-blood contact 
(e.g. through sharing of blood-contaminated 
needles by drug users) and sexual contact. It is 
also transmitted vertically from mother to infant 
during or soon after birth. Infected individuals 
develop an acute infection, which may or may not 
result in symptoms. The majority of those infected 
during adulthood make a full recovery and acquire 
immunity from future infection. Only about 2–10% 
of infected adults will develop CHB, defined as 
viraemia and hepatic inflammation that persists for 
more than 6 months after acute infection with HBV. 
In contrast, almost 100% of infected neonates and 
about 50% of infected young children will develop 
CHB if infected with HBV. 
Active infection can be described as HBeAg 
positive or HBeAg negative according to whether 
hepatitis B ‘e’ antigen (HBeAg) is secreted. HBeAg 
is an indicator of viral replication, although some 
variant forms of the virus do not express HBeAg. 
The response to treatment and rates of progression 
differ between the two forms. People can be 
infected with the so-called HBeAg-negative form of 
the virus initially, or the viral mutation can emerge 
later in the course of infection in people initially 
infected with the HBeAg-positive form of the virus. 
Chronic infection with mutant strains of HBV 
that do not produce the ‘e’ antigen (i.e. HBeAg 
negative) is associated with a fluctuating course and 
a poor prognosis.
The Department of Health estimates that about 
180,000 people in the UK have CHB. There are 
about 7700 new cases of CHB each year. Of these, 
around 300 people were infected within the UK; 
the remainder (mainly immigrants to the UK) 
were infected abroad, generally in areas of high 
prevalence where the virus is frequently transmitted 
from mother to child. 
The progression to cirrhosis occurs at an annual 
rate of 2–5.5%, with a cumulative 5-year rate of 
progression of 8–20% in HBeAg-positive CHB and 
an annual rate of 8–10% in HBeAg-negative CHB. Health Technology Assessment 2009; Vol. 13: Suppl. 3
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Scope of the ERG report
The ERG critically evaluated the evidence 
submission from Bristol Myers Squibb on the use 
of entecavir for the treatment of CHB. Entecavir 
has a marketing authorisation in the UK for the 
treatment of chronic HBV infection in adults 
with compensated liver disease and evidence 
of active viral replication, persistently elevated 
serum alanine aminotransferase (ALT) levels and 
histological evidence of active inflammation and/or 
fibrosis. 
The population considered in the scope was adults 
with CHB according to the licensed indication. 
Patient subgroups included those with HBeAg-
positive and HBeAg-negative CHB and those 
who are treatment (nucleoside analogue) naive or 
refractory to lamivudine (e.g. those with persistent 
viraemia and/or genotypical resistance). Patients 
with coinfections were excluded in accordance with 
the scope. The intervention was entecavir alone in 
the treatment of CHB. 
Comparators included the nucleoside analogues 
lamivudine and telbivudine; the nucleotide 
analogue adefovir dipivoxil; and the immune 
modifiers interferon alpha-2a and -2b and 
pegylated interferon alpha-2a. 
Outcomes included HBeAg/HBsAg seroconversion 
rate, virological response (HBV DNA), histological 
improvement (liver inflammation and fibrosis), 
biochemical response (e.g. ALT levels), 
development of viral resistance and adverse events. 
Outcomes included in the scope and decision 
problem, but not reported in the submission 
include time to treatment failure, survival (unless 
within the context of adverse events) and health-
related quality of life. 
Methods 
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process. 
The ERG checked the literature searches and 
applied the NICE critical appraisal checklist to 
the included studies and checked the quality of 
the manufacturer’s submission with the Centre 
for Reviews and Dissemination (CRD) quality 
assessment criteria for a systematic review. 
In addition, the ERG checked and provided 
commentary on the manufacturer’s model using 
standard checklists. A one-way sensitivity analysis, 
scenario analysis and a probabilistic sensitivity 
analysis were undertaken by the ERG.
Results 
Summary of submitted 
clinical evidence
The manufacturer’s systematic review included 
five randomised controlled trials (RCTs), all of 
which compared entecavir with lamivudine. Three 
of the trials were conducted in nucleoside-naive 
patients (one in HBeAg-positive patients, one 
in HBeAg-negative patients and one in a mixed 
HBeAg-positive and HBeAg-negative status group). 
The other two were conducted in lamivudine-
refractory patients (one in HBeAg-positive 
patients, the other in a mixed HBeAg-positive 
and HBeAg-negative status group). Outcome 
data were reported for up to 1 year of treatment, 
and for a subset of patients who did not achieve a 
complete response and who continued treatment 
in year 2. Cumulative proportions of all patients 
ever attaining a treatment response up to 2 years 
were also presented. Some of the patients from 
the RCTs have entered long-term observational 
extension studies, with treatment continuing for up 
to 5 years; however, fully published data are not yet 
available. 
After 1 year of treatment entecavir was statistically 
superior to lamivudine in terms of the proportion 
of patients achieving HBV DNA suppression, ALT 
normalisation and histological improvement. 
There was no statistically significant difference 
between the treatments in the proportion of 
patients achieving HBeAg seroconversion (HBeAg-
positive patients only, by definition). Most of 
the entecavir-treated patients did not have any 
detectable resistance-associated substitutions at 
1 year of treatment. The proportions of patients 
with any adverse events or serious adverse events 
were similar for entecavir and lamivudine. The 
proportions of patients who withdrew during the 
first year because of adverse events were similar 
for entecavir and lamivudine except in one trial 
in which significantly more lamivudine patients 
withdrew. The number of deaths during treatment 
was low (< 1% in all cases).
The manufacturer also constructed a mixed 
treatment comparison (MTC) model to compare 
entecavir with the comparator drugs in nucleoside-
naive patients. An MTC was not considered 
possible in lamivudine-refractory patients because Entecavir for the treatment of chronic hepatitis B infection
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of lack of evidence. The results of the MTC 
generally accord with the results of the RCTs in 
that, with the exception of HBeAg seroconversion, 
entecavir was superior to lamivudine across 
outcomes. The MTC suggests that entecavir is 
either significantly better or equivalent to the other 
comparators, depending on the outcome measure 
and the time point. 
Summary of submitted cost-
effectiveness evidence
The manufacturer’s economic evaluation 
comprised a systematic review of economic 
evaluations of CHB treatments and a cost–utility 
analysis based on a de novo economic model. 
Two Markov state transition models were 
constructed, one in HBeAg-positive patients and 
one in HBeAg-negative patients. The models 
estimated progression to 14 health states (15 
in the HBeAg-negative model) representative 
of progressive CHB-related liver disease (e.g. 
compensated and decompensated cirrhosis, 
hepatocellular carcinoma). The models had a 
lifetime horizon and a cycle length of 1 year.
In HBeAg-positive and -negative nucleoside-naive 
patients, the models compared entecavir with 
lamivudine, pegylated interferon alpha-2a and 
telbivudine. Treatment lasted for 2 years in HBeAg-
positive patients and 5 years in HBeAg-negative 
patients (with the exception of pegylated interferon 
alpha-2a, which was given for only 1 year). In 
HBeAg-positive patients who were refractory to 
lamivudine, entecavir was compared with adefovir 
added to lamivudine for 2 years. Response to 
treatment was defined by HBeAg seroconversion 
and undetectable HBV DNA.
In HBeAg-positive patients the base-case 
incremental cost-effectiveness ratio (ICER) for 
entecavir compared with lamivudine was £14,329 
per quality-adjusted life-year (QALY). Compared 
with pegylated interferon alpha-2a the ICER was 
£8403 per QALY. Entecavir was associated with 
the same number of QALYs as telbivudine, but 
at a slightly higher total cost and was therefore 
dominated. In HBeAg-negative patients the 
base-case ICERs for entecavir compared with 
lamivudine, pegylated interferon alpha-2a and 
telbivudine were £13,208, £7511 and £6907 per 
QALY respectively. In HBeAg-positive lamivudine-
refractory patients entecavir dominated adefovir 
added to lamivudine. 
One-way deterministic sensitivity analysis for 
entecavir compared with lamivudine on all key 
input parameters, and performed for nucleoside-
naive patients, showed that the results were most 
sensitive to the baseline transition probabilities 
from CHB to seroconversion (spontaneous 
seroconversion) and active cirrhosis, the baseline 
transition probability from active cirrhosis to 
decompensated cirrhosis, baseline cirrhosis risk 
and treatment effects. ICERs generally remained 
under £30,000 per QALY. 
The probabilistic sensitivity analysis in nucleoside-
naive HBeAg-positive patients showed that 
the probability of the ICER for entecavir being 
below £20,000 per QALY was 57% compared 
with lamivudine, 82% compared with pegylated 
interferon alpha-2a and 45% compared with 
telbivudine. In nucleoside-naive HBeAg-negative 
patients the probabilities were 90%, 100% and 96% 
respectively. 
The manufacturer included a lifetime treatment 
scenario in HBeAg-negative patients and the ERG 
included a scenario of up to 20 years treatment for 
HBeAg-positive patients. The ICERs increased as a 
consequence, particularly in the latter case.
The ERG updated the sensitivity analyses with 
utilities and drug costs varied by ± 20%. The model 
for HBeAg-positive patients was most sensitive to 
changes in response and CHB utility rates and the 
transition probabilities from CHB to compensated 
cirrhosis and CHB to seroconversion. The model 
for HBeAg-negative patients was most sensitive 
to changes in the response rates and resistance 
utility and the transition probabilities between 
compensated cirrhosis and decompensated 
cirrhosis and between CHB treatment and 
compensated cirrhosis. 
The ERG conducted a probabilistic sensitivity 
analysis using wider uncertainty around the utilities 
(± 10%) and drug costs (± 20%) than presented 
in the manufacturer’s submission. In the HBeAg-
positive model, patients with CHB were treated for 
2 years with entecavir, lamivudine or telbivudine, 
but it was considered more appropriate for them to 
be treated for longer. The ERG attempted to run 
the HBeAg-positive model for a longer duration 
but the results were inconsistent with those from 
the deterministic scenario analyses.
The ERG ran the HBeAg-negative model for 
a lifetime treatment duration. The model was Health Technology Assessment 2009; Vol. 13: Suppl. 3
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amended so that patients with compensated 
cirrhosis would also receive treatment, lasting 
until they developed decompensated cirrhosis, 
hepatocellular carcinoma or died. As can be seen 
from Figure 1 the probability of entecavir being 
cost-effective at a willingness to pay of £20,000 and 
£30,000 was 4% and 40% respectively.
Commentary on 
the robustness of 
submitted evidence
Strengths
The manufacturer conducted a systematic search 
for clinical effectiveness and cost-effectiveness 
studies of entecavir. It appears unlikely that the 
searches missed any additional trials that would 
have met the inclusion criteria. 
The five entecavir RCTs identified were of 
generally good methodological quality and 
measured a range of outcomes that are appropriate 
and clinically relevant, although health-related 
quality of life was not reported. Overall, the 
manufacturer’s submission presents an unbiased 
estimate of the efficacy of entecavir versus 
lamivudine, based on the results of the five RCTs. 
Overall, the manufacturer’s economic evaluation 
accords with the decision problem and the NICE 
reference case. The approach to modelling was 
generally considered reasonable and the model was 
judged to be internally and externally consistent, 
subject to some uncertainties (see Conclusions). 
Disease progression pathways assumed in the 
economic models were generally consistent with the 
natural history of CHB, although there were some 
concerns about some of the structural assumptions 
(see Conclusions).
Weaknesses
The MTC suffers from certain limitations in 
conduct and reporting, including small numbers 
of studies/single studies in some networks, no 
assessment or discussion of heterogeneity and 
no reporting of criteria for judging statistical 
significance or equivalence. 
Conclusions
Areas of uncertainty
Given the concerns about the conduct and 
reporting of the MTC the ERG considers its results 
to be uncertain. This limits any conclusions that 
can be drawn regarding the comparative efficacy 
of entecavir and telbivudine and entecavir and 
pegylated interferon alpha-2a in nucleoside-naive 
patients (notwithstanding the head-to-head RCT 
evidence comparing entecavir with lamivudine). 
There is relatively limited clinical effectiveness 
and cost-effectiveness evidence for entecavir in 
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lamivudine-refractory patients. Head-to-head RCT 
evidence is available for entecavir versus ongoing 
lamivudine but only in HBeAg-positive patients. 
Smaller RCTs have been published comparing 
switching to adefovir versus adding adefovir to 
ongoing lamivudine, but these have not been 
compared in a statistical indirect comparison 
to entecavir. The manufacturer presented cost-
effectiveness estimates only for HBeAg- positive, 
not HBeAg-negative, lamivudine-refractory 
patients. 
Structural assumptions in both the HBeAg-positive 
and HBeAg-negative disease models precluded 
the patients with response from directly entering 
the active/compensated cirrhosis health state. The 
rationale for this assumption was not clear and 
it is not possible to estimate the impact of these 
structural assumptions. 
Treatment of CHB in many patients will be 
longer than the 2 and 5 years assumed in the 
HBeAg-positive and HBeAg-negative disease 
models respectively. However, there is a paucity 
of published clinical effectiveness data from 
RCTs beyond the second year of treatment [long-
term observational studies (up to 5 years) are in 
progress]. Increasing the treatment duration in 
scenario analysis resulted in higher ICERs. 
No data were presented in the submission on the 
efficacy and safety of entecavir in combination with 
other licensed agents. 
Contrary to the assumptions in the manufacturer’s 
economic evaluation, a certain proportion of 
CHB patients will first present with compensated 
cirrhosis. Moreover, it is unlikely that treatment 
will be terminated once patients progress to the 
active cirrhosis stage of disease. Changing these 
assumptions to reflect a more realistic scenario 
increased the ICER for entecavir compared with 
lamivudine. 
Summary of NICE guidance 
issued as a result of the STA 
The Final Appraisal Determination issued by NICE 
in June 2008 states that:
Entecavir, within its marketing authorisation, is 
recommended as an option for the treatment of 
people with chronic HBeAg-positive or HBeAg-
negative hepatitis B in whom antiviral treatment is 
indicated.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of febuxostat 
for the management of hyperuricaemia in 
patients with gout based upon a review of the 
manufacturer’s submission to the National Institute 
for Health and Clinical Excellence (NICE) as 
part of the single technology appraisal (STA) 
process. The submission’s evidence came from 
two randomised controlled trials comparing the 
efficacy and safety of febuxostat with allopurinol. 
The trials were of reasonable methodological 
quality and measured a clinically relevant range 
of outcomes. A pooled clinical efficacy analysis 
showed that a daily dose of 80 mg or 120 mg 
of febuxostat was significantly more effective 
than fixed-dose allopurinol (300/100 mg/day) at 
lowering serum uric acid (sUA) levels to therapeutic 
targets (< 6 mg/dl); however, a large percentage 
of febuxostat patients did not achieve the 
primary end point and the fixed-dose allopurinol 
regimen may have introduced bias. There were no 
differences between treatments in more clinically 
important outcomes such as gout flares and 
tophi resolution after 52 weeks of treatment. No 
subgroup analyses were conducted for patients with 
renal impairment, non-responders to allopurinol 
or patients with severe disease. Supplementary 
data from a 2-year open-label extension study 
were also provided, but were difficult to interpret 
and poorly reported. The incidence of adverse 
events was similar between treatments, although 
more febuxostat recipients discontinued 
treatment prematurely. A decision tree model was 
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developed to determine the cost-effectiveness 
of febuxostat. The scope was limited to the 
comparison of continual febuxostat treatment 
with continual allopurinol treatment. Switching 
between treatments or withdrawing treatment 
in patients whose sUA levels had not decreased 
was not permitted. The model predicted a cost-
effectiveness of £16,324 [95% confidence interval 
(CI) £6281 to £239,928] per quality-adjusted 
life-year (QALY) gained for febuxostat compared 
with allopurinol after 2 years of treatment. The 
incremental cost per QALY was below £20,000 in 
63% of the simulations undertaken. Changes in the 
time horizon did not materially affect the results. 
The ERG believes that the modelling structure 
employed was not appropriate to estimate the 
cost-effectiveness of febuxostat within a treatment 
algorithm. In addition, there were concerns 
about the methodology used for collecting data 
on key model inputs. Given these reservations 
the cost-effectiveness of febuxostat could not be 
determined. The guidance issued by NICE in 
August 2008 as a result of the STA states that 
febuxostat is recommended as an option for the 
management of chronic hyperuricaemia in gout 
only for people who are intolerant of allopurinol or 
for whom allopurinol is contraindicated.
Introduction 
The National Institute of Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1,2 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the manufacturer’s evidence submission 
is submitted by the evidence review group (ERG), 
an external organisation independent of NICE. 
This paper presents a summary of the ERG report 
for the STA of febuxostat for the management of 
hyperuricaemia in patients with gout.3
Description of the 
underlying health problem
Gout is a metabolic disorder that causes acute, 
intermittent and painful attacks of arthritis in the 
joints of the foot (especially the big toe), knee, 
hand and wrist. Gout occurs when there is a 
sudden onset of inflammation as a result of excess 
uric acid (crystals of monosodium urate) in the 
blood (hyperuricaemia) and tissues. Urate crystals 
deposited in and around joints and tissue are 
known as tophi,4 which can cause significant pain. 
The incidence of gout has been estimated to range 
from 11.9 to 18.0 cases per 10,000 patient-years.�5 
Incidence is affected by both age and gender, 
with men aged from 65 to 84 years having an 
incidence rate approximately 60 times greater than 
that in women aged below 45 years.5 The overall 
prevalence of gout in the UK has been estimated 
at 1.4%,5,6 with this value being 7.3% among men 
aged from 65 to 75 years.5 
Scope of the ERG report
The objective of the appraisal was to assess the 
clinical effectiveness and cost-effectiveness of 
febuxostat for the management of hyperuricaemia 
in adults with gout in whom urate deposition 
has already occurred (including a history or 
presence of tophus and/or gouty arthritis). The 
comparators included: allopurinol, alternative 
standard care (including sulphinpyrazone, 
benzbromarone, probenecid or a combination 
of these) for adults unresponsive to or with 
hypersensitivity to allopurinol, and allopurinol 
(dose adjusted according to glomerular filtration 
rate), benzbromarone or a combination of these 
for adults with renal impairment. The outcomes 
measured included surrogate [serum uric acid 
levels (sUA)] and clinical outcomes (gout flares, 
reduction in tophi size), tolerance and health-
related quality of life. 
The main evidence presented in support of the 
clinical effectiveness of febuxostat was based on two 
head-to-head, phase III, randomised controlled 
trials [the Febuxostat Allopurinol Controlled 
Trial (FACT) study7 and the Allopurinol and 
Placebo-controlled Efficacy study of febuXostat 
(APEX) trial8] comparing the efficacy and safety 
of febuxostat with fixed-dose allopurinol. The 
manufacturer did not present comparisons with 
alternative comparators (such as sulphinpyrazone, Health Technology Assessment 2009; Vol. 13: Suppl. 3
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benzbromarone, probenecid or a combination of 
these) for adults unresponsive to, or intolerant of, 
allopurinol or with renal impairment.
The scope of the manufacturer’s cost-effectiveness 
submission was limited to the comparison of 
continual febuxostat treatment with continual 
allopurinol treatment. Switching between 
treatments was not permitted, nor was there the 
possibility of withdrawing treatment in patients 
whose sUA levels had not decreased. Although 
the dosage level of febuxostat was allowed to vary, 
increasing from 80 mg daily to 120 mg daily in 
patients not initially responding to treatment, the 
dose of allopurinol was assumed fixed at 300 mg 
per day. Costs were considered from an NHS 
and personal social services perspective. Cost-
effectiveness was expressed in terms of incremental 
cost per quality-adjusted life-year (QALY) gained, 
with a time horizon of 2 years used for the base-
case results. 
Methods 
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process. A narrative critique of the 
submitted evidence was presented. The economic 
model submitted by the manufacturer was regarded 
as inappropriate to assess the decision problem.
Results
Summary of submitted 
clinical evidence
A pooled (not meta-analysed) clinical efficacy 
analysis of two head-to-head, multiarm, 
randomised, double-blind, controlled trials (52-
week FACT study7 and 28-week APEX trial8) 
comparing the efficacy and safety of febuxostat 
with fixed-dose allopurinol in 1689 patients with 
hyperuricaemia (sUA levels ≥ 8 mg/dl) and gout 
showed that febuxostat (80 mg/day and 120 mg/
day) was significantly more effective than fixed-
dose allopurinol (300/100 mg/day) at reducing sUA 
levels to < 6 mg/dl. However, a large percentage of 
patients on febuxostat did not achieve the primary 
end point and the fixed-dose regimen employed 
for allopurinol patients may have introduced bias.
Despite the significantly greater effect on sUA 
levels with febuxostat (including mean percentage 
reduction from baseline) than with allopurinol, 
there were generally no differences between 
treatments in more clinically important outcomes 
such as gout flares and tophi resolution (secondary 
end points).
A post hoc subgroup analysis showed that 
febuxostat was more effective than allopurinol in 
decreasing sUA levels to < 6 mg/dl in patients with 
baseline sUA concentrations of < 9 mg/dl, between 
9 and 10 mg/dl and > 10 mg/dl. In addition, 
significantly more febuxostat recipients than fixed-
dose allopurinol recipients achieved a reduction in 
sUA levels to therapeutic targets (< 5 mg/dl). No 
subgroup analyses were conducted for patients with 
renal impairment, non-responders to allopurinol 
or patients with severe disease.
Supplementary data from an ongoing, long-term, 
open-label extension study (EXCEL – fEbuXostat/
allopurinol Comparative Extension Long-term 
study) of the two head-to-head trials showed that 
more patients on febuxostat (80 mg/day and 120 
mg/day) than on fixed-dose allopurinol (300/100 
mg/day) remained on initial treatment after more 
than 24 months of follow-up, and the number of 
tophi and gout flares were reduced over time in 
these patients. However, these data need to be 
interpreted with caution as the manufacturer’s 
submission does not provide statistical analysis 
of event rates over time or data on withdrawals 
because of gout flares, adverse events or non-
response.
Although the adverse event profile was similar 
in those receiving febuxostat compared with 
those receiving allopurinol, more febuxostat 
recipients discontinued treatment prematurely 
[the statistical analysis comparing the rates of 
discontinuation between the treatment groups was 
not reported in the manufacturer’s submission or 
in the requested supplementary data; however, 
the primary published peer-reviewed clinical 
paper for the FACT study reports that the rates 
of discontinuation were significantly higher in 
febuxostat recipients (p < 0.04) than in those 
receiving allopurinol]. Reasons for withdrawal 
included gout flares and adverse events such as 
liver function test abnormalities. 
Summary of submitted cost-
effectiveness evidence
A decision tree model was developed in Microsoft 
excel. The model subdivided patients into four 
mutually exclusive categories of sUA levels, which 
were related to both the expected number of gout 
flares and the underlying utility of a patient. Two Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal
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identical cohorts of men and women entered the 
model with an assumed baseline sUA acid level of ≥ 
8 mg/dl. One cohort was assumed to receive 80 mg/
day of febuxostat treatment, increased to 120 mg/
day in those patients who did not adequately 
respond; the remaining cohort was assumed to 
receive 300 mg/day of allopurinol. The primary 
analysis was for a period of 2 years; however, 
sensitivity analyses were undertaken using different 
time periods.
The manufacturer’s submission predicted a 
cost-effectiveness of £16,324 (95% CI £6281 
to £239,928) per QALY gained for febuxostat 
compared with allopurinol after 2 years of 
treatment. The incremental cost per QALY 
was below £20,000 in 63% of the simulations 
undertaken. Changes in the time horizon did not 
materially affect the results.
Commentary on 
the robustness of 
submitted evidence
The manufacturer conducted an adequate 
systematic search for clinical effectiveness and cost-
effectiveness studies of febuxostat for the treatment 
of gout. It appears unlikely that any additional 
trials would have met the inclusion criteria had the 
search been widened to include other databases. 
The processes undertaken by the manufacturer for 
screening studies, data extraction and applying 
quality criteria to included studies are not explicitly 
clear in the submission. These factors limit the 
robustness of the systematic review. 
The two identified trials, which represent the 
main clinical efficacy evidence, were of reasonable 
methodological quality (with some limitations) 
and measured a range of outcomes that are as 
appropriate and clinically relevant as possible. 
Although a simple pooled analysis of the individual 
patient level data from the two head-to-head 
trials was undertaken by the manufacturer, the 
methods for this type of data pooling were not 
explicitly described. The statistical approach for 
combining the data appears to be inappropriate as 
it fails to preserve randomisation and introduces 
bias and confounding. The resulting pooled 
data should therefore be treated with caution. A 
meta-analysis undertaken by the ERG showed 
that the methodology used by the manufacturer 
to synthesise the data was unlikely to alter the 
conclusions on efficacy.
The ERG considered the modelling structure 
inappropriate. Given the nature of the disease 
and the interventions it was deemed likely that a 
treatment algorithm that started all patients on the 
relatively inexpensive allopurinol and which treated 
those who did not respond with the more expensive 
febuxostat would be more cost-effective than the 
strategies evaluated in the submission. The ERG 
requested that the following analysis be undertaken 
at a minimum: allopurinol – febuxostat – no 
treatment; febuxostat – allopurinol – no treatment; 
allopurinol – no treatment and febuxostat – no 
treatment; however, the manufacturer did not 
comply with this request. 
Even overlooking the inappropriateness of the 
model structure there were a number of errors 
within the analyses presented. For example, the 
price of allopurinol was incorrect and the price 
of febuxostat was altered within the probabilistic 
sensitivity analyses. Reanalyses were not undertaken 
by the manufacturer despite these issues being 
raised.
The ERG has serious concerns regarding the data 
selected to estimate the relationship between sUA 
levels and the number of gout flares expected. A 
large portion of the data collected to develop this 
linkage was excluded (accounting for 51% of all 
patients and 77% of UK patients), and the ERG 
was not convinced by the arguments provided to 
exclude these data.
The ERG has additional serious concerns about 
the interpretation of the multivariate analyses. It 
is indicated that there is no significant association 
between sUA levels and the number of gout flares 
reported within the data set used. This analysis has 
apparently been overlooked in favour of a bivariate 
analysis that does not include other confounders. 
Note that, although no statistically significant 
relationship was found within this data set, this 
does not mean that such a relationship does not 
exist, as indicated in clinical guidelines.
The ERG noted that the chronic utility gain 
associated with reduced sUA levels was a key driver 
in the cost per QALY gained ratio. It was noted 
that the relationship between sUA level and chronic 
utility had been modelled assuming a linear 
relationship. The evidence for this assumption was 
uncertain and not clearly established.
The ERG noted that the derivation of the disutility 
associated with a gout flare came from data that did Health Technology Assessment 2009; Vol. 13: Suppl. 3
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not appear internally consistent, with some people 
giving greater utility to a health state associated 
with a gout flare than to one without such a flare. 
The ERG further noted that the dose of allopurinol 
was assumed to be fixed, whereas guidelines allow 
for the upwards titration of this dose. Although the 
manufacturer reported that the dose of allopurinol 
commonly used was 300 mg/day, this does not 
represent best practice, which allows for doses of 
900 mg/day of allopurinol. 
Conclusions
The clinical evidence, based on a simple pooled 
analysis of the patient level data from two 
randomised controlled trials, showed that a 
daily dose of 80 mg or 120 mg of febuxostat was 
significantly more efficacious than allopurinol at 
the commonly used fixed daily dose of 300 mg in 
lowering sUA levels to therapeutic targets (< 6 mg/
dl). However, a large percentage of patients 
on febuxostat did not achieve the primary end 
point and the fixed-dose regimen employed for 
allopurinol patients may have introduced bias. 
In general, there were no differences between 
treatments in more clinically important outcomes 
such as gout flares and tophi resolution after 52 
weeks of treatment. No subgroup analyses were 
conducted for patients with renal impairment, 
non-responders to allopurinol or patients with 
severe disease. Supplementary data from a 2-year 
open-label extension study were also provided, but 
were difficult to interpret (no statistical analysis 
undertaken) and poorly reported. 
The ERG believes that the modelling structure 
employed was not appropriate to estimate the 
cost-effectiveness of febuxostat within a treatment 
algorithm. In addition, there were concerns 
about the methodology used for collecting data 
on key model inputs. Given these reservations 
the cost-effectiveness of febuxostat could not be 
determined. 
Key issues 
The head-to-head trials presented in the 
manufacturer’s submission directly compared 
febuxostat with fixed-dose allopurinol. However, 
gout management guidelines and the allopurinol 
summary of product characteristics generally 
recommend dose titration of allopurinol according 
to therapeutic targets (usual maintenance dose in 
mild conditions 100–200 mg/day, in moderately 
severe conditions 300–600 mg/day, in severe 
conditions 700–900 mg/day). Nevertheless, the 
manufacturer’s submission and our clinical advisors 
suggest that dose escalation is rarely used by most 
clinicians in clinical practice. 
Although measures such as gout flares and tophi 
resolution were secondary outcomes, these are 
more clinically important. Randomised controlled 
trial evidence shows that even though more 
febuxostat recipients achieved the recommended 
biochemical goal (< 6 mg/dl) this did not translate 
into an advantage over allopurinol in clinically 
important outcomes. 
As previously described, the ERG has serious 
concerns regarding the model structure (and 
choice of treatment algorithms compared) and the 
robustness of key parameters within the model.
Areas of uncertainty
There is uncertainty around the clinical 
effectiveness and cost-effectiveness of febuxostat in 
comparison to other relevant treatments (including 
sulphinpyrazone, benzbromarone, probenecid or 
a combination of these) for adults unresponsive 
to, or intolerant of, allopurinol or with renal 
impairment. In addition, long-term efficacy and 
safety data are limited on febuxostat and there is 
uncertainty around the relationship between sUA 
levels and the expected number of gout flares.
The incremental costs per QALY of sequential 
approaches of treatment are uncertain as these 
approaches have not been modelled. The inclusion 
of sequential treatments is likely to produce a 
more cost-effective solution than allowing only one 
treatment for the duration of the model. Moreover, 
there is uncertainty in the relationship between 
sUA levels and underlying patient utility.
Summary of NICE guidance 
issued as a result of the STA 
The appraisal consultation document issued by 
NICE in May 2008 stated that:
Febuxostat is not recommended for the 
management of chronic hyperuricaemia in people 
with gout.
The manufacturer appealed against the 
preliminary decision and produced additional 
evidence not contained in the STA submission 
that compared febuxostat with no treatment. This 
evidence was not formally critiqued by the ERG.Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal
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In August 2008 the final appraisal determination 
was released with the guidance that febuxostat, 
within its marketing authorisation, is recommended 
as an option for the management of chronic 
hyperuricaemia in gout only for people who are 
intolerant of allopurinol or for whom allopurinol is 
contraindicated. 
Intolerance of allopurinol was defined as:
adverse effects that are sufficiently severe to 
warrant its discontinuation, or to prevent full 
dose escalation for optimal effectiveness as 
appropriate within its marketing authorisation. 
At the time of writing the manufacturer was 
appealing this decision.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of rivaroxaban 
for the prevention of venous thromboembolism 
(VTE) in adult patients undergoing elective hip 
or knee replacement surgery based upon a review 
of the manufacturer’s submission to the National 
Institute for Health and Clinical Excellence 
(NICE) as part of the single technology appraisal 
(STA) process. The submission’s evidence came 
from four randomised controlled trials (RCTs) 
comparing rivaroxaban with enoxaparin [RECORD 
(Regulation of Coagulation in Orthopedic 
surgery to pRevent Deep venous thrombosis and 
pulmonary embolism) 1–4] and three comparing 
dabigatran with enoxaparin [RE-NOVATE (the 
prevention of venous thromboembolism after 
total hip replacement trial), RE-MODEL (the 
prevention of venous thromboembolism after total 
knee replacement trial) and RE-MOBILIZE (the 
prevention of venous thromboembolism after total 
knee arthroplasty trial)]. The evidence from the 
four RECORD trials indicates that rivaroxaban had 
superior efficacy over enoxaparin after total hip 
replacement (THR) and total knee replacement 
(TKR). For the composite primary outcome 
of any deep vein thrombosis (DVT), non-fatal 
pulmonary embolism (PE) and death from all 
causes the relative risk reductions were 70–79% 
in THR and 31–49% in TKR. Rivaroxaban also 
had superior efficacy over enoxaparin for the 
secondary outcome major VTE. Rivaroxaban was 
not inferior to enoxaparin on the safety outcome 
of major bleeding. After the correction of some 
errors found by the ERG, the manufacturer’s 
economic model represented a reasonable model 
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of patients receiving prophylaxis for THR or 
TKR. In the base-case analyses rivaroxaban 
dominated both enoxaparin and dabigatran. The 
incremental costs saved and quality-adjusted life-
years (QALYs) gained were small (below £200 
and 0.005, respectively, per person). Analyses 
were conducted sampling from the distributions 
observed from the RCTs. When all parameters were 
sampled rivaroxaban dominated enoxaparin in 
all scenarios except for two, in which enoxaparin 
produced more QALYs than rivaroxaban and had 
an incremental cost per QALY gained of £5000 
and £8000 respectively. Rivaroxaban dominated 
dabigatran when RECORD 1 and RECORD 2, 
individually or pooled, were compared with RE-
NOVATE and when all four rivaroxaban RCTs 
pooled were compared with all three dabigatran 
RCTs. Dabigatran dominated rivaroxaban 
comparing RECORD 4 with RE-MODEL and 
RE-MOBILIZE, and was more cost-effective than 
rivaroxaban comparing RECORD 3 (incremental 
cost per QALY gained of rivaroxaban compared 
with dabigatran of £123,000) or RECORD 3 
and RECORD 4 pooled (incremental cost per 
QALY gained of dabigatran compared with 
rivaroxaban of £400) with RE-MODEL and 
RE-MOBILIZE. In conclusion, the evidence 
indicates that rivaroxaban is not inferior to 
enoxaparin in terms of the primary and secondary 
outcomes. The submission presents a reasonable 
estimation of the cost-effectiveness of rivaroxaban 
compared with enoxaparin and dabigatran, 
although the uncertainty in the decision has 
been underestimated. The results are particularly 
sensitive to any assumed difference in the number 
of fatal PEs, but the ERG does not believe there is 
sufficient evidence to support a difference between 
interventions. The NICE guidance issued as a 
result of the STA states that: riveroxaban, within 
its marketing authorisation, is recommended 
as an option for the prevention of venous 
thromboembolism in adults having elective THR or 
elective TKB.
Introduction 
The National Institute of Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the 
STA of rivaroxaban for the prevention of venous 
thromboembolism (VTE),2 which followed a 
manufacturer’s submission by Bayer Schering 
Pharma.3
Description of the 
underlying health problem
The manufacturer’s submission reported that there 
are approximately 25,000 deaths each year in 
England due to VTE. This figure includes not only 
those undergoing surgery but also those admitted 
to hospital for the medical care of serious illnesses 
and will overestimate deaths associated with total 
hip and knee replacement.3
Scope of the ERG report
The manufacturer’s submission reported on the 
clinical and cost-effectiveness of rivaroxaban 
(Xarelto®) for the prevention of VTE in adult 
patients undergoing elective hip or knee 
replacement surgery. The recommended dose 
of rivaroxaban is 10 mg taken orally once daily. 
The duration of treatment recommended in the 
summary of product characteristics depends on the 
type of orthopaedic surgery. Patients undergoing 
total hip replacement (THR) have a recommended 
treatment duration of 5 weeks; this value is 2 weeks 
for total knee replacement (TKR). The acquisition 
cost of rivaroxaban reported in the manufacturer’s 
submission was £4.50 per day.
The manufacturer’s submission considered 
enoxaparin, a low-molecular-weight heparin 
(LMWH), as the most relevant comparator, as 
reflected in the scope. A weighted comparison 
against all LMWHs was presented as a sensitivity 
analysis assuming equal efficacy between all 
LMWHs. Indirect comparisons with dabigatran Health Technology Assessment 2009; Vol. 13: Suppl. 3
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(which NICE has recommended as an option for 
the primary prevention of venous thromboembolic 
events in adults who have undergone elective 
THR or elective TKR4) were undertaken. The 
majority of outcome measures identified in the 
scope [mortality, incidence of symptomatic and 
asymptomatic VTE, pulmonary embolism (PE)], 
and safety outcomes (bleeding events), were 
reported. However, outcomes relating to knee and 
hip joints, although identified in the scope, were 
not reported. 
Clinical data on effectiveness were taken from four 
randomised controlled trials (RCTs) of rivaroxaban 
compared with enoxaparin [RECORD (Regulation 
of Coagulation in Orthopedic surgery to pRevent 
Deep venous thrombosis and pulmonary embolism) 
1–45–8] and from three RCTs of dabigatran 
compared with enoxaparin [RE-NOVATE (the 
prevention of venous thromboembolism after 
total hip replacement trial),9 RE-MODEL(the 
prevention of venous thromboembolism after total 
knee replacement trial)10 and RE-MOBILIZE (the 
prevention of venous thromboembolism after total 
knee arthroplasty trial)11].
The manufacturer submitted a model in Microsoft 
excel. The model was divided into a prophylaxis 
stage (a period of 35 days for THR and 12 days 
for TKR), a postprophylaxis stage (until 3 months 
after surgery) and a long-term complication stage 
(assumed to end when a patient died or became 
101 years of age). The initial two stages were 
assessed using a decision trees, whereas the third 
phase was divided into a 5-year period, in which 
VTE, post-thrombotic syndrome (PTS) or death 
could occur, followed by a duration in which only 
transitions to death were allowed. The base case in 
the manufacturer’s submission assumed that only 
those parameters that were statistically significantly 
different would be varied between rivaroxaban and 
the comparator. Additional analyses requested by 
the ERG used all variables regardless of statistical 
significance.
Methods
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process. 
The searches performed by the manufacturer 
were examined by the ERG and found to be 
satisfactory. Repeat searches were performed by 
the ERG and no additional relevant trials were 
identified. The ERG is confident that all relevant 
studies were included in the manufacturer’s 
submission and details of ongoing trials that are 
likely to be reporting additional evidence within 
12 months were reported. The inclusion/exclusion 
criteria appeared to be appropriate; they included 
appropriate detail and a rationale for the inclusion 
and exclusion criteria was provided. The reasons 
provided for excluding studies were all justified. 
The manufacturer’s submission reported on efforts 
to ensure blinding but did not report if any of these 
studies assessed the success of blinding, as required 
by point 11 on the Consolodated Standards of 
Reporting Trials (CONSORT) checklist (www.
consort-statement.org/). The view of the ERG is 
that such assessments were not undertaken.
The manufacturer’s submission answered 
the questions suggested by NICE for validity 
assessment. The ERG assessed the validity of the 
three published trials (RECORD 1, RECORD 2 
and RECORD 3) and the trial information for 
RECORD 4. This was found to be satisfactory and 
of adequate methodological quality.
The manufacturer’s submission used the modified 
intention-to-treat (MITT) population in the 
analyses of the trials. The MITT population was 
defined as the number of patients who were: (1) 
valid for safety analysis; (2) had the appropriate 
surgery; and (3) had an adequate assessment of 
thromboembolism. The ERG judged this to be an 
appropriate approach.
The manufacturer’s submission contained a series 
of meta-analyses. Each comparison was conducted 
initially using a fixed-effects model, with a 
random-effects model performed if heterogeneity 
was observed between studies. Theoretically this 
approach is incorrect as a decision on the most 
appropriate model should be made before analysis, 
but this methodology did not materially affect the 
conclusions.
The deterministic results produced by the model 
matched those reported in the manufacturer’s 
submission. The results from probabilistic 
sensitivity analyses were not checked because 
the ERG found errors within the model. These 
errors were identified by a thorough, although 
not exhaustive, review of the model structure and 
internal logic and the responsiveness of the results 
to changes in parameter values. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal
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Results 
Summary of submitted 
clinical evidence
In RECORD 1, 3 and 4, rivaroxaban was 
demonstrated to have superior efficacy over 
enoxaparin after THR and TKR. RECORD 2 also 
demonstrated superiority comparing 35 days of 
rivaroxaban with 12–14 days of enoxaparin. Based 
on the composite primary end point of any deep 
vein thrombosis (DVT), non-fatal PE and death 
from all causes the relative risk reductions were 
70–79% in THR and 31–49% in TKR. Rivaroxaban 
was also demonstrated to have superior efficacy 
over enoxaparin in RECORD 1, 2 and 3 for the 
secondary end point of major VTE. Superior 
efficacy was also shown for the symptomatic VTE 
end point in RECORD 2 and RECORD 3. 
There were no adverse events that were 
significantly different between rivaroxaban and 
enoxaparin. Major bleeding occurred more 
frequently in patients on rivaroxaban. Individually 
there was no statistically significant difference 
in major bleed rates between patients receiving 
rivaroxaban and those receiving enoxaparin, 
although all point estimates favoured enoxaparin 
treatment. On meta-analysing all four RCTs, the 
results remained non-significant in a fixed-effects 
model (p = 0.697). The point estimate favoured 
enoxaparin rather than rivaroxaban (relative 
risk 1.8516, 95% CI 0.9434 to 3.6340). Clinical 
evidence, where not commercial-in-confidence, 
is presented in Chapter 6 of the manufacturer’s 
submission.
The indirect comparison with dabigatran was 
marked as commercial-in-confidence in the 
manufacturer’s submission.
Summary of submitted cost-
effectiveness evidence
In the base-case analyses rivaroxaban was shown 
to dominate [i.e. produce more quality-adjusted 
life-years (QALYs) at a lower cost] both enoxaparin 
and dabigatran. The incremental costs saved and 
QALYs gained were small (typically below £200 and 
0.005, respectively, per person). 
Analyses were conducted sampling from the 
distributions observed from the RCTs (or indirect 
comparison with dabigatran) regardless of statistical 
significance. These results were firmly driven by 
the assumed impact on fatal PE. Unfortunately this 
parameter was excluded within the probabilistic 
sensitivity analyses, which rendered the uncertainty 
generated in the remaining parameters as largely 
redundant. Using RECORD 4 alone, enoxaparin 
produced more QALYs than rivaroxaban and 
had an incremental cost per QALY gained of 
approximately £5000; using the pooled results 
this value was approximately £8000. These results 
imply that enoxaparin was more cost-effective 
than rivaroxaban in both of these scenarios using 
current recommended thresholds.12
When dabigatran was used as the comparator, 
rivaroxaban dominated dabigatran when RECORD 
1 individually, RECORD 2 individually or the 
pooled results from RECORD 1 and RECORD 
2 were compared with RENOVATE and when all 
four rivaroxaban RCTs pooled were compared 
with all three dabigatran RCTs. Dabigatran 
dominated rivaroxaban using RECORD 4 
compared with RE-MODEL and RE-MOBILIZE, 
and was more cost-effective than rivaroxaban 
using RECORD 3 compared with RE-MODEL and 
RE-MOBILIZE (an incremental cost per QALY 
gained of rivaroxaban compared with dabigatran 
of approximately £123,000) and when RECORD 3 
and RECORD 4 were pooled and compared with 
RE-MODEL and RE-MOBILIZE (an incremental 
cost per QALY gained of dabigatran compared with 
rivaroxaban of approximately £400).
Commentary on 
the robustness of 
submitted evidence
Appropriate analyses and comparisons were 
included in the manufacturer’s submission. Data 
on the final primary outcome measure (all-cause 
mortality) were not presented or meta-analysed. 
The ERG have inferred that this was due to no 
additional deaths bar fatal PE, the data for which 
were presented as commercial-in-confidence. The 
ERG has no concerns with the methodology used 
for the evidence syntheses. The reporting and 
interpretation of the safety data were good.
Following dialogue iterations with the ERG team, 
the resultant excel file was a reasonable model of 
patients receiving prophylaxis for THR or TKR. 
The iterations were needed to amend errors 
found by the ERG, which included incorrect use of 
standard errors, probabilities becoming negative 
and some cells being incorrectly cleared. 
The probabilistic sensitivity analyses did not 
capture all of the uncertainty present within 
the decision. The number of total VTEs for 
rivaroxaban is assumed to equal the rates observed Health Technology Assessment 2009; Vol. 13: Suppl. 3
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in the appropriate RCT(s). For both rivaroxaban 
and the comparator the proportions of total VTEs 
that are symptomatic, non-fatal and fatal are fixed 
at the rates observed in the appropriate RCTs. 
These are relatively small numbers. For example, in 
RECORD 1 there were 18 VTEs of which four were 
non-fatal PE; fixing the proportion of non-fatal 
PEs to 0.22 (4/18) of the total VTEs will result in 
considerable uncertainty being excluded compared 
with a more appropriate approach of sampling 
this value from a beta distribution. The long-term 
effects of major bleeding, in particular those that 
are intracranial, were excluded from the model, 
although the manufacturer subsequently conducted 
an external calculation which showed that this 
omission did not markedly affect the results for the 
comparison with enoxaparin. The ERG conducted 
a similar calculation for the comparison with 
dabigatran, with similar conclusions. 
Following the postprophylaxis stage of the model 
all VTE events are assumed to be DVT. This is 
conservative and will be unfavourable to the 
intervention that has the lowest number of VTEs, 
which is generally rivaroxaban.
The utility of a patient was set to that of a 50-year-
old and does not decline as the simulated patient 
ages. This will favour the intervention that 
has the greater estimated number of patients 
alive following the postprophylaxis stage. The 
manufacturer conducted additional analyses to 
assess the impact of altering the underlying utility, 
with only a minor reduction in the incremental 
QALYs gained associated with rivaroxaban. The 
manufacturer concluded that the inaccuracy 
introduced by not altering the utility will be small. 
The ERG agrees with this conclusion.
Conclusions 
The manufacturer’s search strategy was adequately 
reported and the submission appears to contain all 
of the relevant head-to-head RCTs. The outcomes 
selected were relevant and appropriate, although 
joint outcomes, included in the final scope issued 
by NICE, were excluded as none of the trials 
reported this.
Processes and validation of study screening and 
data extraction appear to be appropriate. Statistical 
methods were explicitly described for the meta-
analyses and indirect comparisons and all relevant 
analyses were performed, although reporting of 
the results of these analyses were limited because 
of the omission of conclusions or plots to aid 
interpretation. The manufacturer’s submission 
appears to contain an unbiased estimate of the 
treatment effect of rivaroxaban in relation to the 
relevant outcomes and the comparator enoxaparin. 
Overall the evidence from the four RECORD trials 
in the manufacturer’s submission indicates that 
rivaroxaban 10 mg once daily is not inferior to 
the comparator enoxaparin in terms of the total 
VTE and all-cause mortality, symptomatic VTE, 
non-fatal PE and fatal PE. Rivaroxaban was also 
indicated not to be inferior to the comparator on 
the safety outcome of major bleeding.
The ERG believes that, following iterations with 
the ERG, the manufacturer’s submission represents 
a reasonable estimation of the cost-effectiveness 
of rivaroxaban compared with enoxaparin 
and dabigatran, although the uncertainty in 
the decision has been underestimated. This is 
important as the costs and QALYs accrued by all 
interventions were similar and the incremental 
differences reported were small, typically below 
£200 and 0.005, respectively, per person.
The ERG notes that the results are particularly 
sensitive to any assumed difference in the number 
of fatal PEs, but does not believe that there is 
sufficient evidence to support a difference between 
interventions. 
Summary of NICE guidance 
issued as a result of the STA 
The guidance states that:
Rivaroxaban, within its marketing authorisation, is 
recommended as an option for the prevention of 
venous thromboembolism in adults having elective 
THR or elective TKB.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of cetuximab 
for recurrent and/or metastatic squamous cell 
carcinoma of the head and neck (SCCHN) 
based upon a review of the manufacturer’s 
submission to the National Institute for Health 
and Clinical Excellence (NICE)  as part of the 
single technology appraisal (STA) process. 
The submission’s evidence came from a single 
reasonably high-quality randomised controlled 
trial (RCT) [EXTREME (Erbitux in First-Line 
Treatment of Recurrent or Metastatic Head and 
Neck Cancer); n = 442] comparing cetuximab plus 
chemotherapy (CTX) with CTX alone. Cetuximab 
plus CTX had significant effects compared with 
CTX alone on the primary outcome of overall 
survival (10.1 versus 7.4 months respectively) 
and the secondary outcomes of progression-free 
survival (PFS) (5.6 versus 3.3 months), best overall 
response to therapy (35.6% versus 19.5%), disease 
control rate (81.1% versus 60%) and time-to-
treatment failure (4.8 versus 3.0 months), but not 
on duration of response (5.6 months versus 4.7 
months). No safety issues with cetuximab arose 
beyond those already previously documented. The 
manufacturer developed a two-arm state-transition 
Markov model to evaluate the cost-effectiveness 
of cetuximab plus CTX versus CTX alone, using 
clinical data from the EXTREME trial. The ERG 
recalculated the base-case cost-effectiveness results 
taking changes in parameters and assumptions 
into account. Subgroup and threshold analyses 
were also explored. The manufacturer reported 
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an incremental cost-effectiveness ratio (ICER) of 
£121,367 per quality-adjusted life-year (QALY) 
gained and an incremental cost per life-year gained 
of £92,226. Univariate sensitivity analysis showed 
that varying the cost of day-case infusion and the 
utility values in the stable/response health state 
of the cetuximab plus CTX arm had the greatest 
impact on the ICER. Probabilistic sensitivity 
analysis illustrated that cetuximab plus CTX 
is unlikely to be cost-effective for patients with 
recurrent and/or metastatic SCCHN, even at what 
would usually be considered very high levels of 
willingness to pay for an additional QALY. With 
regard to the economic model the appropriateness 
and reliability of parametric survival projection 
beyond the duration of trial data could not be fully 
explored because of lack of information. The ERG 
also questioned the appropriateness of economic 
modelling in this STA as evidence is available 
only from a single RCT. In conclusion, the ERG 
considers that patients with metastatic SCCHN 
were not shown to receive a significant survival 
benefit from cetuximab plus CTX compared with 
CTX alone and that even setting a lower price for 
cetuximab would not strengthen the manufacturer’s 
case for cost-effectiveness. 
Introduction 
The National Institute of Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the 
STA of cetuximab for recurrent and/or metastatic 
squamous cell carcinoma of the head and neck 
(SCCHN).2 
Description of the 
underlying health problem
The term head and neck cancer covers a 
wide variety of different cancers [30 different 
International Classification of Diseases (ICD) 
codes] occurring in the tissues of the head and 
neck. As a group they account for over 8000 cancer 
registrations in England and Wales.3 Around 
90% of head and neck cancers are squamous cell. 
SCCHN most commonly arises in the oral cavity, 
pharynx and larynx.3 The number of registrations 
for these subgroups was 5833 in England in 20054 
and 446 in Wales in 2006,5 with a ratio of male to 
female cases of approximately 70:30. 
There is no standard treatment for all patients 
with recurrent or metastatic disease; guidelines 
recommend the tailoring of therapy to the 
individual patient.3,6 In some patients the tumour 
may still be amenable to surgery or radiotherapy 
with curative intent; however, in patients with 
metastatic disease or who have previously received 
radiotherapy for the initial tumour, this may not 
be possible. For this group of patients palliative 
CTX is the mainstay of treatment if they are 
able to tolerate it. The most commonly used 
chemotherapeutic treatments for recurrent and/
or metastatic SCCHN include methotrexate, 
bleomycin, 5-fluorouracil (5-FU) and platinum 
compounds. The prognosis for recurrent and/or 
metastatic SCCHN subjects is poor with a median 
survival time of only 6–9 months.
Scope of the ERG report
The ERG report presents the results of the 
assessment of the manufacturer (Merck Serono) 
evidence submission regarding the use of 
cetuximab with platinum-based CTX (cisplatin 
plus fluorouracil or carboplatin plus fluorouracil) 
compared with platinum-based CTX alone for the 
first-line treatment of recurrent and/or metastatic 
SCCHN. The report includes an assessment of 
both the clinical effectiveness and cost-effectiveness 
evidence submitted by the manufacturer. The 
primary clinical outcome measure was overall 
survival (OS), with secondary outcomes of 
progression-free survival (PFS), response to 
therapy, safety and quality of life (QoL). The 
cost-effectiveness measures were incremental cost-
effectiveness ratio (ICER) and incremental cost per 
life-year (LY) gained. Health Technology Assessment 2009; Vol. 13: Suppl. 3
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Cetuximab (Erbitux®) is a monoclonal antibody 
that inhibits the action of the epidermal growth 
factor receptor (EGFR), which is highly expressed 
in nearly all SCCHN tumours. Whilst the ERG 
report was in progress, a positive opinion from the 
European Medicines Agency (EMEA) Committee 
for Medicinal Products for Human Use (CHMP) 
to extend the use of cetuximab to include the 
treatment of patients with recurrent and/or 
metastatic SCCHN in combination with platinum-
based CTX was issued. Final approval was given by 
the EMEA after the submission of the ERG report. 
Neither the EMEA nor NICE limited the indication 
to first-line use; this limitation was imposed by the 
manufacturer.
Methods 
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process. 
The ERG evaluated the quality of the 
manufacturer’s clinical effectiveness review. 
Searches conducted by the manufacturer were 
assessed for completeness and the single trial put 
forward as evidence of effectiveness was critically 
appraised using a standard tool (CASP7 – Critical 
Appraisal Skills Programme). With regard to 
cost-effectiveness evidence, the ERG assessed 
the manufacturer’s searches for completeness, 
critically appraised the submitted economic model 
using a standard assessment tool (Drummond and 
Jefferson8) and conducted a detailed evaluation 
of the model. The ERG recalculated the base-
case cost-effectiveness results taking changes in 
parameters and assumptions into account, for 
example revised drug costs, mid-cycle correction, 
overall PFS utility value. Subgroup and threshold 
analyses were also explored by the ERG.
Results 
Summary of submitted 
clinical evidence
The clinical effectiveness evidence described 
in the manufacturer’s submission was derived 
from a single phase III open-label randomised 
controlled trial (RCT) that compared the use 
of cetuximab plus CTX with CTX alone. The 
EXTREME (Erbitux in First-Line Treatment of 
Recurrent or Metastatic Head and Neck Cancer) 
trial was conducted in 80 centres within 17 
European countries and included 442 patients. The 
results of the EXTREME trial showed significant 
effects of cetuximab plus CTX compared with 
CTX alone on the primary outcome of OS (10.1 
months versus 7.4 months respectively). There 
was also a significant effect of cetuximab plus 
CTX compared with CTX alone on the secondary 
end points of median PFS (5.6 months versus 3.3 
months), best overall response to therapy (35.6% 
versus 19.5%), disease control rate (81.1% versus 
60%) and median time-to-treatment failure (TTF) 
(4.8 months versus 3.0 months). No significant 
difference was noted in the median duration of 
response between the cetuximab plus CTX and 
CTX alone groups (5.6 months versus 4.7 months). 
The results are summarised in Table 1. The QoL 
data described were very limited; the manufacturer 
states that there was no difference in QoL between 
the two treatment groups. No safety issues related 
to cetuximab arose beyond those already previously 
documented.
Summary of submitted cost-
effectiveness evidence
In the absence of UK-based economic evaluations, 
the manufacturer conducted a de novo economic 
evaluation. A two-arm state-transition Markov 
model was developed to evaluate the cost-
effectiveness of cetuximab plus CTX compared 
with CTX alone. The clinical data used in the 
economic evaluation were generated from the 
EXTREME trial. Although the economic evaluation 
was trial based there was also a modelling 
component with regard to the extrapolation of 
health effects beyond the period of the trial (24 
months). The economic evaluation adopted a 
lifetime horizon for the consideration of costs and 
benefits and the perspective is that of the UK NHS 
and personal social services.
The manufacturer reported an ICER of £121,367 
per quality-adjusted life-year (QALY) gained and 
an incremental cost per LY gained of £92,226. In 
addition to the main results, ICERs for selected 
subgroups were also presented. Univariate 
sensitivity analysis showed that varying (1) the cost 
of day-case infusion and (2) the utility values in the 
stable/response health state of the cetuximab plus 
CTX arm had the greatest impact on the ICER. 
Probabilistic sensitivity analysis illustrated that 
cetuximab plus CTX is unlikely to be cost-effective 
for patients with recurrent and/or metastatic 
SCCHN, even at what would usually be considered 
very high levels of willingness to pay for an 
additional QALY. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
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The manufacturer argued that the assessment of 
QoL associated with the use of cetuximab plus CTX 
may misrepresent the real health gain for patients 
with recurrent and/or metastatic SCCHN. The 
manufacturer would prefer that other indicators of 
benefit (e.g. socioeconomic status) are taken into 
account.
Commentary on 
the robustness of 
submitted evidence
The manufacturer cited evidence from a reasonably 
high-quality trial (EXTREME) of the clinical 
benefit of cetuximab plus CTX compared with 
CTX alone. The trial was well designed, used 
robust randomisation techniques and was suitably 
powered to show differences between the treatment 
groups. Appropriate exploratory subgroup analyses 
were carried out and statistical reporting was 
generally good. 
However, the clinical effectiveness evidence was 
based only on this single trial, which was open label 
and relied on the unblinded assessment of clinical 
outcomes. Despite designing the trial to include a 
comprehensive analysis of QoL, very limited QoL 
data were collected and reported. 
The manufacturer provided clinical evidence 
to support the use of cetuximab as a first-line 
treatment for patients with recurrent and/or 
metastatic SCCHN; hence, there is no discussion 
of the costs and benefits of second-line treatment 
options for this patient group. Neither the final 
scope issued by NICE nor the EMEA CHMP 
positive opinion limits the use of cetuximab to first-
line treatment only. 
The ERG was confident that neither model 
assumptions nor parameter values were likely to 
introduce sufficient uncertainty to allow cetuximab 
plus CTX to be cost-effective for this group of 
patients. A number of key issues and parameters in 
the economic model did not seem to be justified. 
The results of the ERG’s threshold analysis indicate 
that cetuximab plus CTX may not be cost-effective 
at any price according to current NICE guidance. 
The ERG identified a number of different areas in 
the economic model in which it was appropriate to 
correct or revise model assumptions, which taken 
together increased the size of the ICER (Table 2).
Conclusions 
The EXTREME trial demonstrated the superior 
clinical effectiveness of cetuximab plus CTX over 
CTX alone. However, whether or not the patients 
in the EXTREME trial are sufficiently similar (in 
terms of age and Karnofsky Performance Status) 
to patients in England and Wales with recurrent 
and/or metastatic SCCHN who require treatment 
TABLE 1  Key results of the EXTREME trial
Outcome
Cetuximab plus 
CTX (n = 222) CTX (n = 220)
Hazard ratio (HR)/
odds ratio (OR) p-value
Primary
OS (months), median (95% CI)  10.1 (8.6–11.2) 7.4 (6.4–8.3) HR 0.797 (0.644–0.986) 0.00362a
Secondary
PFS (months), median (95% CI)a 5.6 (5.0–6.0) 3.3 (2.9–4.3) HR 0.538 (0.431–0.672) < 0.001
Best overall response 35.6% (29.3–42.3) 19.5% (14.5–25.4) OR 2.326 (1.504–3.600) < 0.001b
Disease control rate (95% CI)c 81% (75.3–86.0) 60% (53.2–66.5) OR 2.881 (1.870–4.441) < 0.001d
Time to treatment failure (months) (95% CI)a 4.8 (4.0–5.6) 3.0 (2.8–3.4) HR 0.59 (0.48–0.73) < 0.001b
Duration of response (months) (95% CI)e 5.6 (4.7–6.0) 4.7 (3.6–5.9) HR 0.76 (0.50–1.17) 0.21b
CI, confidence interval; CTX, chemotherapy; OS, overall  survival; PFS, progression-free survival.
p-values, hazard ratios and odds ratios are stratified according to receipt or non-receipt of previous chemotherapy and 
Karnofsky Performance Status at randomisation.
a  Number of months estimated using Kaplan–Meier method.
b  p-value calculated using the log-rank test.
c  Disease control includes complete response, partial response and stable disease.
d  p-value calculated using Cochrane–Mantel–Haenszel test.
e  Data on duration of response were available for 62 patients in the cetuximab group and 36 patients in the CTX alone 
group; data on disease progression in these patients were available at the time of analysis. The number of months was 
estimated using the Kaplan–Meier method.Health Technology Assessment 2009; Vol. 13: Suppl. 3
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is uncertain. There is also no clinical evidence 
available to demonstrate the effectiveness of 
cetuximab plus CTX in patients who are not 
cetuximab naive. Finally, the ERG considered 
that patients with metastatic SCCHN were not 
shown to receive a significant survival benefit from 
cetuximab plus CTX compared with CTX alone. 
With regards to the economic model, some 
questions over the appropriateness and reliability 
of parametric survival projection beyond the 
duration of trial data could not be fully explored 
by the ERG because of lack of information; in 
particular, the appropriateness of employing 
Weibull modelling for all patient groups may 
benefit from further examination. The ERG also 
questioned the appropriateness of economic 
modelling in this STA as many health economists 
would prefer to carry out direct evaluation of trial 
data when evidence is available only from a single 
RCT.
The cost per QALY figures reported in the 
manufacturer’s submission were high (in excess 
of £100,000 per QALY gained). Both the original 
model submitted by the manufacturer and the 
model corrected/adjusted by the ERG yielded 
ICERs that far exceed accepted values. Given 
the high cost of cetuximab plus CTX and the 
marginal health benefits gained in comparison to 
CTX, discussion of further economic issues within 
NICE’s current acceptability range (from £20,000 
to £30,000 per QALY) seemed unnecessary. The 
ERG concluded that even setting a lower price for 
cetuximab would not strengthen the manufacturer’s 
case for cost-effectiveness. 
Summary of NICE guidance 
issued as a result of the STA 
At the time of writing, the guidance has not been  
issued by NICE. 
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of ustekinumab 
for the treatment of moderate to severe psoriasis 
based upon a review of the manufacturer’s 
submission to the National Institute for Health 
and Clinical Excellence (NICE) as part of the 
single technology appraisal (STA) process. The 
submission’s main evidence came from three 
randomised controlled trials (RCTs), of reasonable 
methodological quality and measuring a range of 
clinically relevant outcomes. Higher proportions 
of participants treated with ustekinumab (45 mg 
and 90 mg) than with placebo or etanercept 
achieved an improvement on the Psoriasis Area 
and Severity Index (PASI) of at least 75% (PASI 
75) after 12 weeks. There were also statistically 
significant differences in favour of ustekinumab 
over placebo for PASI 50 and PASI 90 results, 
and for ustekinumab over etanercept for PASI 90 
results. A weight-based subgroup dosing analysis 
for each trial was presented, but the methodology 
was poorly described and no statistical analysis to 
support the chosen weight threshold was presented. 
The manufacturer carried out a mixed treatment 
comparison (MTC); however, the appropriateness 
of some of the methodological aspects of the 
MTC is uncertain. The incidence of adverse 
events was similar between groups at 12 weeks and 
withdrawals due to adverse events were low and less 
frequent in the ustekinumab than in the placebo or 
etanercept groups; however, statistical comparisons 
were not reported. The manufacturer’s economic 
model of treatments for psoriasis compared 
ustekinumab with other biological therapies. The 
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model used a reasonable approach; however, 
it is not clear whether the clinical effectiveness 
estimates from the subgroup analysis, used in 
the base-case analysis, were methodologically 
appropriate. The base-case incremental cost-
effectiveness ratio for ustekinumab versus 
supportive care was £29,587 per quality-adjusted 
life-year (QALY). In one-way sensitivity analysis 
the model was most sensitive to the number of 
hospital days associated with supportive care, the 
cost estimate for intermittent etanercept 25 mg 
and the utility scores used. In the ERG’s scenario 
analysis the model was most sensitive to the price 
of ustekinumab 90 mg, the proportion of patients 
with baseline weight > 100 kg and the relative 
risk of intermittent versus continuous etanercept 
25 mg. In the ERG’s probabilistic sensitivity 
analysis ustekinumab had the highest probability 
of being cost-effective at conventional NICE 
thresholds, assuming the same price for the 45-mg 
and 90-mg doses; however, doubling the price of 
ustekinumab 90 mg resulted in ustekinumab no 
longer dominating the comparators. In conclusion, 
the clinical effectiveness and cost-effectiveness of 
ustekinumab in relation to other drugs in this class 
is uncertain. Provisional NICE guidance issued 
as a result of the STA states that ustekinumab is 
recommended as a treatment option for adults with 
plaque psoriasis when a number of criteria are met. 
Final guidance is anticipated in September 2009.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, for which most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
of ustekinumab for the treatment of psoriasis.
Description of the 
underlying health problem
Psoriasis is a chronic systemic inflammatory skin 
disease. The most common form of psoriasis is 
chronic plaque psoriasis. This is characterised by 
exacerbations of thickened, erythematous, scaly 
patches of skin that can occur at any skin site but 
commonly appear on the elbows, knees, scalp 
and trunk. Estimates suggest that psoriasis affects 
approximately 2% of the population in the UK.2 
Psoriasis is associated with a significant negative 
impact on heath-related quality of life.
The severity of psoriasis is determined by 
several factors and can vary from mild, through 
to moderate and severe. A number of different 
criteria are available for determining the severity 
of psoriasis. One of the main accepted systems for 
classifying the severity of psoriasis is the Psoriasis 
Area and Severity Index (PASI). The limitations 
of this measure have been well documented3 but 
despite its shortcomings it is the measure used in 
most clinical trials. Body surface area (BSA) and 
the Dermatology Life Quality Index (DLQI) are 
also commonly used. Severe psoriasis is generally 
accepted as a PASI ≥ 10 when combined with 
a DLQI > 102 or, if taken alone, a PASI > 12.4 
Moderate psoriasis is generally defined as a PASI 
between 7 and 12.4 
Scope of the ERG report
The ERG critically evaluated the evidence 
submission from Janssen-Cilag on the use of 
ustekinumab for the treatment of moderate to 
severe plaque psoriasis. 
Ustekinumab is a fully human monoclonal 
antibody. The licensed indication for ustekinumab 
for injection is for the treatment of adults with 
moderate to severe chronic plaque psoriasis who 
have had an inadequate response to or who have a 
contraindication to or who are intolerant to other 
systemic therapies.
The outcomes stated in the manufacturer’s 
definition of the decision problem were measures 
of severity of psoriasis, remission rate, relapse rate, 
adverse effects of treatment and health-related 
quality of life.Health Technology Assessment 2009; Vol. 13: Suppl. 3
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Methods 
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process. 
The ERG checked the literature searches and 
applied the NICE critical appraisal checklist to 
the included studies and checked the quality of 
the manufacturer’s submission with the Centre 
for Reviews and Dissemination (CRD) quality 
assessment criteria for a systematic review. 
In addition, the ERG checked and provided 
commentary on the manufacturer’s model using 
standard checklists. One-way sensitivity analyses, 
scenario analyses and a probabilistic sensitivity 
analysis were undertaken by the ERG.
Results 
Summary of submitted 
clinical evidence
The main evidence on efficacy in the submission 
came from three randomised controlled trials 
(RCTs), two comparing ustekinumab with placebo 
and one comparing ustekinumab with etanercept. 
One further RCT contributed to the evidence on 
adverse events.
Higher proportions of participants treated with 
ustekinumab (at both the 45-mg and 90-mg doses) 
than with placebo (two trials) or etanercept (one 
trial) achieved an improvement on the PASI of at 
least 75% (PASI 75) after 12 weeks. No statistical 
comparisons between the two ustekinumab doses 
were presented for any of the trials. There were 
also statistically significant differences in favour of 
ustekinumab (at both the 45-mg and 90-mg doses) 
over placebo for the proportion of participants 
achieving a PASI 50 and a PASI 90 (two trials), 
but again no statistical comparisons between the 
two ustekinumab doses were presented. In the 
trial comparing ustekinumab with etanercept, 
PASI 50 results appeared to be similar across 
the three treatment groups (45 mg ustekinumab, 
90 mg ustekinumab and etanercept), but no 
statistical comparison of these data was presented. 
In contrast, both doses of ustekinumab led to 
statistically significantly higher proportions of 
participants achieving a PASI 90 than was observed 
in the etanercept group.
The manufacturer’s submission also presented 
PASI 75 data from a weight-based subgroup dosing 
analysis for each of the three included trials, but 
the methodological description of these analyses 
was limited and no statistical analysis to support 
the chosen weight threshold was presented.
The manufacturer’s submission did not present a 
narrative or quantitative synthesis of the data from 
the three included trials except as part of a mixed 
treatment comparison (MTC). The MTC was 
conducted using data from the ustekinumab trials 
in two ways, either all participants as randomised 
or subgroups of participants from the dose by 
weight analysis noted above. The result from the 
all participant analysis MTC for treatment with 
45 mg ustekinumab was a mean probability of 
achieving a PASI 75 response to treatment of 69%, 
with a different result obtained from the weight-
based ustekinumab analysis MTC. For the 90-mg 
ustekinumab dose the all participant analysis 
MTC resulted in a mean probability of achieving 
a PASI 75 response to treatment of 74%; again, a 
different result was obtained from the weight-based 
ustekinumab analysis MTC. For the PASI 75 MTC 
outcome the probability of response was greatest 
for infliximab, and the probability of response with 
ustekinumab was greater than those of the other 
comparators, except for infliximab. 
For the reported secondary outcomes there were 
statistically significant differences in favour of 
ustekinumab over placebo and etanercept in 
the Physician’s Global Assessment score, and in 
favour of ustekinumab over placebo in the DLQI. 
The DLQI outcome was not reported for the 
ustekinumab versus etanercept trial. The incidence 
of adverse events appeared to be similar in the 
treatment and placebo arms at 12 weeks although 
this was not statistically tested. Withdrawals due 
to adverse events were low and appeared to occur 
less often in the ustekinumab groups than in either 
the placebo or the etanercept groups, although 
a statistical comparison was not reported in the 
manufacturer’s submission.
Summary of submitted cost-
effectiveness evidence
The manufacturer’s economic evaluation included 
a review of the published economic literature on 
therapies used for psoriasis and a report of an 
economic evaluation undertaken for the NICE 
STA process, which included a cost-effectiveness 
model of treatments for psoriasis comparing 
ustekinumab with other biological therapies. The 
analysis estimated the number of individuals who 
responded to treatment at each time interval, 
the mean length of time that an individual Ustekinumab for the treatment of moderate to severe psoriasis
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would respond to treatment and the utility gains 
associated with this response. The model was based 
closely on the model reported in Woolacott and 
colleagues.3
The model was generally internally consistent 
and appropriate to psoriasis in terms of structural 
assumptions. The cost-effectiveness analysis 
generally conformed to the NICE reference case, 
the scope and the decision problem.
The evidence-based treatment effectiveness was 
reported in terms of the probability of achieving 
a specified PASI response with each of the 
treatment alternatives and supportive care by the 
end of the trial period. Evidence was synthesised 
from a variety of trials for ustekinumab and the 
comparators using an MTC model. In the base-case 
analysis it was assumed that those under a weight 
of 100 kg (80% of patients in base case) received 
45 mg ustekinumab whereas those over 100 kg 
(20% of patients) received 90 mg ustekinumab. 
The manufacturer’s submission proposed a patient 
access scheme (PAS) providing ustekinumab 90 mg 
at an equivalent cost to ustekinumab 45 mg and the 
model assumed these costs in the base case.
Patients who achieved improvements in PASI 
score were assigned an associated improvement in 
quality of life (a utility gain), with higher responses 
associated with larger improvements in quality 
of life. Two approaches were used to achieve 
this task. In the first the observed patient-level 
changes in DLQI were used as surrogate outcomes 
in the statistical modelling that related the PASI 
scores to utility gains assessed using the EuroQol 
5 dimension (EQ-5D) questionnaire. The EQ-5D 
utility values derived from the DLQI were used 
in the base-case analysis. In the second approach 
the observed patient-level Short Form-36 (SF-36) 
scores were converted into Short Form-6D (SF-6D) 
utility values and aggregated according to the PASI 
response categories. The SF-6D utility estimates 
were used in the sensitivity analysis. 
The base-case incremental cost-effectiveness ratio 
for ustekinumab compared with supportive care 
for patients with severe psoriasis was £29,587 per 
quality-adjusted life-year (QALY). The one-way 
sensitivity analysis reported in the manufacturer’s 
submission shows that the model was most sensitive 
to the number of hospital days associated with 
supportive care, the estimate of the cost of dosing 
for intermittent etanercept 25 mg and the use of 
SF-6D utility scores instead of EQ-5D utility scores 
(with SF-6D utility scores associated with a much 
higher cost-effectiveness ratio for ustekinumab 
in comparison to supportive care then the cost-
effectiveness ratio estimated in the base-case 
analysis).
Scenario analyses were presented in the 
manufacturer’s submission that compared 
outcomes from the model when the efficacy 
estimates came from (1) the MTC subgroup 
data in which the ustekinumab dose regimen 
depends on the baseline weight and (2) the 
all patients according to their randomisation 
outcome. Scenario analysis conducted by the ERG 
showed that the model was most sensitive to the 
assumptions about the price of ustekinumab 90 mg, 
the proportion of patients with baseline weight 
> 100 kg and the relative risk of intermittent 
etanercept 25 mg in comparison to continuous 
etanercept 25 mg. 
The ERG amended the manufacturer’s probabilistic 
sensitivity analysis to include distributions for 
parameters not previously included in the model. 
Figure 1 shows the cost-effectiveness acceptability 
curve assuming the same price for the 45-mg and 
90-mg doses of ustekinumab. According to these 
results ustekinumab has the highest probability 
of being cost-effective at conventional NICE 
thresholds, whereas all other biologics have a zero 
probability of being cost-effective. The probability 
of ustekinumab being cost-effective at thresholds 
of £20,000 and £30,000 per QALY is 10% and 47% 
respectively.
Commentary on 
the robustness of 
submitted evidence
Strengths
The manufacturer conducted a systematic search 
for clinical effectiveness and cost-effectiveness 
studies of ustekinumab. It appears unlikely that the 
searches missed any additional trials that would 
have met the inclusion criteria.
The three key ustekinumab trials identified 
and systematically reviewed were of reasonable 
methodological quality and measured a range of 
outcomes that are as appropriate and clinically 
relevant as possible. Overall, the manufacturer’s 
submission presents an unbiased estimate of 
treatment efficacy for ustekinumab at 12 weeks 
based on the results of two placebo-controlled 
trials and one trial comparing ustekinumab with 
etanercept.Health Technology Assessment 2009; Vol. 13: Suppl. 3
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The economic model presented in the 
manufacturer’s submission used a reasonable 
approach.
Weaknesses
There is a lack of information regarding the 
methodology used for the subgroup analysis and 
it was therefore difficult for the ERG to determine 
whether the methods used were appropriate and 
whether the subgroup analysis supports the weight-
based categorisation presented. These clinical 
effectiveness estimates of the subgroup data were 
used in the base-case analysis of the modelled 
economic evaluation of ustekinumab presented in 
the manufacturer’s submission. 
Conclusions 
Areas of uncertainty
The reliability of the estimates of clinical 
effectiveness derived from subgroups of 
participants receiving differential weight-based 
dosing is uncertain. In addition, the impact on 
MTC outcomes of using a fixed-effect model rather 
than a random-effects model (which was used by 
the assessment group who developed the original 
MTC) is unclear.
The clinical effectiveness and cost-effectiveness of 
ustekinumab in relation to other drugs in the class 
is uncertain. A number of factors contribute to this 
uncertainty, including the two points above but also 
the assumption about the proportion of patients 
with baseline weight > 100 kg and the assumptions 
about the relative risk of intermittent etanercept 
25 mg in comparison to continuous etanercept 
25 mg.
It is not clear whether the estimates from the 
subgroup analysis, which were used in the base-
case analysis in the manufacturer’s submission, 
were methodologically appropriate. The choice 
of utility estimates used for the cost-effectiveness 
analysis has a major impact on the estimated cost-
effectiveness of ustekinumab.
Key issues 
Two of the trials of ustekinumab efficacy presented 
by the manufacturer were placebo-controlled trials. 
There was also one head-to-head RCT that directly 
compared ustekinumab with etanercept 50 mg. 
No studies were identified that directly compared 
ustekinumab with the other possible comparators 
included within the STA. 
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The manufacturer’s submission did not present 
the results of the subgroup analysis according to 
NICE methodological guidance and therefore the 
ERG was unable to determine whether the weight-
based categorisation used in the cost-effectiveness 
analysis was justified.
Although the manufacturers carried out an MTC, 
the effectiveness of ustekinumab in relation to 
other drugs of this type remains unclear because of 
uncertainties about the appropriateness of some of 
the methodological aspects of the MTC.
All of the economic outcomes in the manufacturer’s 
submission were conditional on the price of 
ustekinumab 90 mg as indicated in the PAS. 
Doubling the price of ustekinumab 90 mg resulted 
in ustekinumab no longer dominating the 
comparators at a cost-effectiveness threshold of 
£20,000–30,000 per QALY.
Summary of NICE guidance 
issued as a result of the STA 
The NICE guidance issued as a result of the STA 
states that ustekinumab is recommended as a 
treatment option for adults with plaque psoriasis 
when the following criteria are met:
•  The disease is severe, as defined by a total 
Psoriasis Area Severity Index (PASI) score of 10 
or more and a Dermatology Life Quality Index 
(DLQI) score of more than 10.
•  The psoriasis has not responded to standard 
systemic therapies, includingciclosporin, 
methotrexate and PUVA (psoralen and long-
wave ultraviolet radiation), or the person is 
intolerant of or has a contraindication to these 
treatments. 
•  The manufacturer provides the 90 mg dose 
(2 × 45 mg vials) for people who weigh more 
than 100 kg at the same total cost as for a 
single 45 mg vial. 
Ustekinumab treatment should be stopped 
in people whose psoriasis has not responded 
adequately by 16 weeks after starting treatment. An 
adequate response is defined as either:
•  a 75% reduction in the PASI score (PASI 75) 
from when treatment started or 
•  a 50% reduction in the PASI score (PASI 50) 
and a 5-point reduction in the DLQI score 
from when treatment started. 
When using the DLQI, healthcare professionals 
should take into account any physical, sensory or 
learning disabilities, or communication difficulties, 
that could affect the responses to the DLQI and 
make any adjustments they consider appropriate.
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